

REFERENCES

- Ahlneck, C. and Zografi, G. 1990. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. **Int. J. Pharm.** 62 : 87-95.
- Alsaiedan, S.M., Alsughayer, A.A. and Eshra, A.G. 1998. Improved dissolution rate of indomethacin by adsorbents. **Drug Dev. Ind. Pharm.** 24(4) : 389-394.
- Amdidouche, D., Darrouzet, H., Duchene, D. and Poelman, M.C. 1989. Inclusion of retinoic acid in β -cyclodextrin. **Int. J. Pharm.** 54 : 175-179.
- Backenfield, T., Muller, B.W., Wiese, M. and Seydel, J.K. 1990. Effect of cyclodextrin derivatives on indomethacin stability in aqueous solution. **Pharm. Res.** 7(5): 484-490.
- Bekers, O., Uijtandaal, E.V., Boijnen, J.H., Butt, A. and Underberg, W.J.M. 1991. Cyclodextrins in pharmaceutical field. **Drug Dev. Ind. Pharm.** 17(11) : 1503-1549.
- Biemann, Klaus. 1983. **Tables of spectra data for structure determine of organic compounds.** (New York : Springer-verlag, 1983), p. I5-I265.
- Blanco, J., Vila, J.L., Otero, F., Anguiana, S. 1991. Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. **Drug Dev. Ind. Pharm.** 17(7) : 943-957.
- Bodmeier, R. and Chen, H. 1988. Preparation of biodegradable poly (l) lactide microparticles using a spray-drying technique. **J. Pharm. Pharmac.** 40 : 754-757.

- Bootsma, H.P.R., Frijlink, H.W., Eissens, A., Proost, J.H., Doome, H.V. and Lerk, C.F. 1989. β -cyclodextrin as an excipient in solid oral dosage forms : in vitro and in vivo evaluation of spray-dried diazepam- β -cyclodextrin products. *Int. J. Pharm.* 51 : 213-223.
- Boudeville, P. and Burgot, J.L. 1995. A new pH-metric methodology for the determination of thermodynamic inclusion constants of guest/cyclodextrin complexes. *J. Pharm. Sci.* 84(9) : 1083-1089.
- Boymond, C. and Ridolfi, H. 1994. Phydicco-chemical study of inclusion compound phenothiazine- β -cyclodextrin. *Drug Dev. Ind. Pharm.* 20(14) : 2183-2193.
- Broadhead , J., Rouan , K.E. and Rhodes , C.T. 1992. The spray drying of pharmaceuticals. *Drug Dev. Ind. Pharm.* 18(11&12) : 1169-1206.
- Broadhead, J., Rovan, S.K., Han, I. and Rhodes, C.T. 1994. The effect of process and formulation variables on the properties of spray-dried galactosidase. *J. Pharm. Pharmac.* 46 : 458-467.
- Buckton, G. and Beezer, A.E. 1992. The relationship between particle size and solubility. *Int. J. Pharm.* 82 : R7-R10.
- Carstensen, J. T. and Morris, T. M. 1993. Chemical stability of Indomethacin in the solid amorphous and molten states. *J. Pharm. Sci.* 82(6) : 657-659.
- Casella, R., Williams, D.A. and Jambhekar, S.S. 1998. Solid-state β -cyclodextrin complexes containing indomethacin, ammonia and water. I. Formulation studies. *Int. J. Pharm.* 165 : 1-14.
- Casella, R., Williams, D.A. and Jambheka, SS : 1998. Solid-state β -cyclodextrin complexes containing indomethacin, ammonia and water. II. Solubility studies. *Int. J. Pharm.* 165 : 15-22.

Chun, I.K. and Yun, D.S. 1993. Inclusion complexation of hydrocortisone butyrate with cyclodextrins and dimethyl- β -cyclodextrin in aqueous solution and in solid state. *Int. J. Pharm.* 96 : 91-103.

Cipiciani, A., Ebert, C., Linda, P., Rubessa, F. and Savelli, B. 1983. Kinetics and mechanism of basic hydrolysis of Indomethacin and related compounds : A Reevaluation. *J. Pharm. Sci.* 72(9) : 1075-1076.

Cipiciani, A., Ebert, C., Germani, R., Linda, P., Lourecich, M., Rubessa, F. and Savelli, G. 1985. Micellar effects on the basic hydrolysis of indomethacin and related compounds. *J. Pharm. Sci.* 74(11) : 1184-1187.

Corrigan, O.I. and Stanley, C.T. 1982. Mechanism of drug dissolution rate enhancement from β -cyclodextrin-drug systems. *J. Pharm. Pharmac.* 34 : 621-626.

Corrigan, O.I., Sabra, K. and Holohan, E.M. 1983. Physicochemical properties of spray dried drugs : phenobarbitone and hydroflumethiazide. *Drug Dev. Ind. Pharm.* 9(1&2) : 1-20.

Corrigan, O.I., Holohan, E.M. and Reilly, M.R. 1985. Physicochemical properties of indomethacin and related compounds co-spray dried with polyvinylpyrrolidone. *Drug Dev. Ind. Pharm.* 11(2&3) : 677-695.

Crosby, E.J. and Marshall, W.R.Jr. 1985. Atomization and spray drying. *Chem. Eng. Prog.* 57(7) : 1104-1112.

Dawson, J.E., Hajratwala, B.R. and Taylor, H. 1977. Kinetics of indomethacin degradation II : presence of alkali plus surfactant. *J. Pharm. Sci.* 66(9) : 1259-1263.

Dhanaraju, M.D., Kumaran, K.S., Baskaran, T. and Moorthy, M. 1998. Enhancement of bioavailability of griseofulvin by its complexation with β -cyclodextrin. *Drug Dev. Ind. Pharm.* 24(6) : 583-587.

Duchene, D. and Wouessidjewe, D. 1990. Pharmaceutical uses of cyclodextrins and derivatives. **Drug Dev. Ind. Pharm.** 16(17) : 2487-2499.

Duchene, D., Vauton, C. and Glomot, F. 1986. Cyclodextrins, Their value in pharmaceutical technology. **Drug Dev. Ind. Pharm.** 12(11-13) : 2193-2215.

Duquemin, S.J. and Nixon, J.R. 1985. The effect of sodium lauryl sulphate, cetrimide and polysorbate 20 surfactants on complex coacervate volume and droplet size. **J. Pharm. Pharmacol.** 37 : 698-702.

Elamin, A.A., Ahlneck, C., Alderborn, G. and Nystrom, C. 1995. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. **Int. J. Pharm.** 111: 159-170.

Erden, N. and Celebi, N. 1988. A study of the inclusion complex of naproxen with β -cyclodextrin. **Int. J. Pharm.** 48 : 83-89.

Espinar, O.F., Anguiano, S., Garcia, N., Vila, J. and Blanco, J. 1992. Interaction of naproxen with β -cyclodextrin in solution and in the solid state. **Int. J. Pharm.** 79 : 149-157.

Fini, A., Fazio, G. and Feroci, G. 1995. Solubility and solubilization properties of non-steroidal anti-inflammatory drugs. **Int. J. Pharm.** 126 : 95-102.

Foster T. and Leatherman M. 1995. Powder characteristics of proteins spray-dried from different spray dryers. **Drug Dev. Ind. Pharm.** 21(15): 1705-1723.

Giordano, F., Gazzaniga, A., Moyano, J.R., Ventura, P., Zanol, M., Peveri, T. and Carima, L. 1997. Crystal forms and piroxicam piralate : preparation and characterization of two polymorphs. **J. Pharm. Sci.** 87(3) : 333-337.

Guyot, M., Fawaz, F., Bildet, J., Bonini, F. and Lagueny, A.-M. 1995. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions. **Int. J. Pharm.** 123 : 53-63.

Hamada, Y., Nambu, N. and Nagai, T. 1975. Interactions of α - and β -cyclodextrin with several non-steroidal antiinflammatory drugs in aqueous solution. **Chem. Pharm. Bull.** 23(6) : 1205-1211.

Hajratwala, B.R. and Dawson, J.E. 1977. Kinetics of Indomethacin degradation I : presence of alkali. **J. Pharm. Sci.** 26(1) : 27-29.

Hassan, M.A., Suleiman, MS and Najib, NM. Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β -cyclodextrin. 1990. **Int. J. Pharm.** 58 : 19-24.

Herzfeld, O.D. and Kummel, R. 1983. Dissociation constants, solubilities and dissolution rates of some selected nonsteroidal antiinflammatories. **Drug Dev. Ind. Pharm.** 9(5) : 767-793.

Imaizumi, H., Nambu, N. and Nagai, T. 1979. Stability and several physical properties of amorphous and crystalline forms of indomethacin. **Chem. Pharm. Bull.** 28(9) : 2565-2569.

Imaizumi, H., Nambu, N. and Nagai, T. 1983. Stabilization of amorphous state of indomethacin by solid dispersion in polyvinylpyrrolidone. **Chem. Pharm. Bull.** 31(7) : 2510-2512.

Jachowicz, R., Numberg, E. and Hoppe, R. 1993. Solid dispersions of oxazepam. **Int. J. Pharm.** 99 : 321-325.

Kawashima, Y., Lin, S.Y., Ueda, M. and Takenaka, H. 1984. Preparation of directly compressible powders of a physical mixture and a complex of theophylline-phenobarbital using spray-drying. **Int. J. Pharm.** 18 : 335-343.

Kawashima, Y., Matsuda, K. and Takenaka, H. 1972. Physicochemical properties of spray-dried agglomerated particles of salicylic acid and sodium salicylate. **J. Pharm. Pharmac.** 24: 505-512.

- Kawashima, Y., Lin, S.Y., Ogawa, M., Handa, T. and Takenaka, H. 1985. Preparations of agglomerated crystals of polymorphic mixtures and a new complex of indomethacin-epizole by the spherical crystallization technique. *J. Pharm. Sci.* 74(11) : 1152-1156.
- Kawashima, Y., Lin, S.Y., Ueda, M. and Takenaka, H. 1983. Preparations of solid particulates of aminopyrine-barbital complex (pyrabital) without autoxidation by a spray drying technique. *Drug Dev. Ind. Pharm.* 9(3) : 285-302.
- Khan, G.M. and Jiabi, Z. 1998. Preparation, characterization and evaluation of physicochemical properties of different crystalline forms of ibuprofen. *Drug Dev. Ind. Pharm.* 24(5) : 463-471.
- Kikuchi, M., Hirayama, F. and Uekama, K. 1987. Improvement of oral and rectal bioavailabilities of carmofur by methylated β -cyclodextrin complexations. *Int. J. Pharm.* 38 : 191-198.
- Krenn, M., Gamcsik, M.P., Vogelsang, G.B., Colvin, O.M. and Leong, K.W. 1992. Improvements in solubility and stability of Thalidomide upon complexation with hydroxypropyl- β -cyclodextrin. *J. Pharm. Sci.* 81(7) : 685-689.
- Kurozumi, M., Nambu, N. and Nagai, T. 1975. Inclusion compounds of non-steroidal antiinflammatory and other slightly water soluble drugs with α - and β -cyclodextrins in powdered form. *Chem. Pharm. Bull.* 23(12) : 3062-3068.
- Kwong, E., Pillai, G. and Mc erlane, K.M. 1982. HPLC analysis of indomethacin and its impurities in capsule and suppository formulations. *J. Pharm. Sci.* 71(7) : 828-830.
- Lin, S.Y., Kao, Y.H. and Yang, J.C. 1988. Grinding effect on some pharmaceutical properties of drugs by adding β -cyclodextrin. *Drug Dev. Ind. Pharm.* 14(1) : 99-118.

- Lin, S.Y. and Kao, Y.H. 1989. Solid particulates of drug- β -cyclodextrin inclusion complexes directly prepared by a spray-drying technique. *Int. J. Pharm.* 56 : 249-259.
- Lin, S.Z., Wouessidjewe, D., Poelman, M.C. and Duchene, D. 1991. Indomethacin and cyclodextrin complexes. *Int. J. Pharm.* 69 : 211-219.
- Loftsson, T. and Brewster, M.E. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. *J. Pharm. Sci.* 85(10) : 1017-1025.
- Loftsson, T. and Petersen, D.S. 1998. Cyclodextrin solubilization of ETH-65, a Zwitterionic drug. *Drug Dev. Ind. Pharm.* 24(14) : 365-370.
- Luner, P.E., Babu, S.R. and Mehta, S.C. 1996. Wettability of a hydrophobic drug by surfactant solutions. *Int. J. Pharm.* 128 : 29-44.
- Maa, Y.F., Nguyen, P.A., Andya, J.D., Dasovich, N., Sweeney, T.D., Shire, S.J. and Hsu, C.C. 1988. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. *Pharm. Res.* 17(5) : 768-775.
- Mall, S., Buckton, G. and Rawlins, P.A. 1996. Slower dissolution rates of sulphamerazine in aqueous sodium dodecyl sulphate solutions than in water. *Int. J. Pharm.* 131 : 41-46.
- Makoto, O. and Yoshihisa, M. 1995. Effect of cogrinding with various kinds of surfactants on the dissolution behavior of phenytoin. *J. Pharm. Sci.* 84(12) : 1434-1437.
- Matsuda, Y., Otsuka, M., Onoe, M. and Tatsumi, E. 1992. Amorphism and physicochemical stability of spray-dried frusemide. *J. Pharm. Pharmac.* 44 : 627-633.

McCanley, J. and Cohen, E.C. 1984. Indomethacin. **Analytical Drug Profile.** p. 212-235.

Mosharraf, M., Sebhatu, T. and Nystrom, C. 1999. The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. **Int. J. Pharm.** 177 : 29-51.

Moyano, J.R., Gines, J.M., Arias, M.J. and Rabasco, A.M. 1995. Study of the dissolution characteristics of oxazepam via complexation with β -cyclodextrin. **Int. J. Pharm.** 114: 95-102.

Muller, W.B. and Brauns, U. 1985. Solubilization of drugs by modified β -cyclodextrins. **Int. J. Pharm.** 26 : 77-88.

Mura, P., Fancci, M.T., Manderioli, A., Feurlanetto, S. and Pinzanti, S. 1998. Thermal analysis as a screening technique in preformulation studies of picotamide solid dosage forms. **Drug Dev. Ind. Pharm.** 24(8) : 747-751.

Na, K. and Lee, K.Y. 1998. pH-sensitive release of indomethacin using Lactam-Acetate microspheres. **Drug Dev. Ind. Pharm.** 24(6) : 563-568.

Nakai, Y., Yamamoto, K., Terada, K. and Watanabe, D. 1987. New methods for preparing cyclodextrin inclusion compound I. Heating in a sealed container. **Chem. Pharm. Bull.** 35(11) : 4609-4615.

Nielson, F. 1982. Spray drying pharmaceuticals. **Manuf. Chem.** 53(7) : 38-41.

Okimoto, K., Rajewski, R.A., Uekama, K., Jona, J.A. and Stella, V.J. 1996. The interaction of charged and uncharged drugs with neutral (HP- β -CD) and anionically charged (SBE7- β -CD) β -cyclodextrins. **Pharm. Res.** 17(2) : 256-264.

Ong, J.T., Chowhan, Z.T. and Samuels, G.J. 1993. Drug-excipient interactions resulting from powder mixing. VI Role of various surfactants. **Int. J. Pharm.** 96 : 231-242.

Otero, E.F., Anguiano, I.S., Garcia, G.N., Vila, J.J. and Blanco, M.J. 1992. Interaction of naproxen with β -cyclodextrin in solution and in the solid state. **Int. J. Pharm.** 79 : 149-157.

Ozdemir, N. and Ordu, S. 1998. Improvement of dissolution properties of furosemide by complexation with β -cyclodextrin. **Drug Dev. Ind. Pharm.** 24(1) : 19-25.

Palmieri, G.F., Wehrle, P. and Stamm, A. 1993. Inclusion of vitamin D₂ in β -cyclodextrin. Evaluation of different complexation methods. **Drug Dev. Ind. Pharm.** 19(8) : 875-885.

Palmieri, G.F., Angeli, D.G., Giovannucci, G. and Martelli, S. 1997. Inclusion of methoxybutropate in β - and hydroxypropyl β -cyclodextrins : comparison and preparation methods. **Drug Dev. Ind. Pharm.** 23(1) : 27-37.

Pitha, J., Milecki, J., Fales, H., Pannel, L. and Uekema, K. 1986. Hydroxypropyl- β -cyclodextrin : preparation and characterization ; effects on solubility of drugs. **Int. J. Pharm.** 29 : 73-82.

Plakogiannis, F.M., Ali, A. and Kazmi, S. 1981. High-pressure liquid chromatographic determination of indomethacin in capsules. **Drug Dev. Ind. Pharm.** 7(2) : 215-221.

Potti, G.K., Gallelli, J.F., Akogyeram, C.O., Ahmadi, B. and Habib, J.M. 1993. Improved dissolution of indomethacin in coprecipitates with phospholipids-II. **Drug Dev. Ind. Pharm.** 19(10) : 1221-1229.

Rajesh, B.G. and Adel, H.K. 1988. Characterization, dissolution and diffusion properties of tolbutamide β -cyclodextrin complex system. **Drug Dev. Ind. Pharm.** 14(5) : 657-682.

- Sanghavi, N.M., Choudhari, K.B., Matharu, R.S. and Viswanathan, L. 1993. Inclusion complexation of lorazepam with β -cyclodextrin. **Drug Dev. Ind. Pharm.** 9(6) : 701-712.
- Seagh, H. 1977. Spray-coating bulk drugs aid dosage form production. **Manu. Chem. And Aerosol News.** 48(4) : 25-35.
- Shahen, O., Othman, S., Jatal, I., Amidi, A. and Al-Turk, W. 1987. Comparison of pharmaceutics and pharmacodynamics of a conventional and a new rapidly dissolving glibenclamide preparartion. **Int. J. Pharm.** 38 : 123-131.
- Shangraw, R.F., Pande, G.S. and Gala, P. 1992. Characterization of the tabletting properties of β -cyclodextrin and the effects of processing variables inclusion complex formation, compactibility and dissolution. **Drug Dev. Ind. Pharm.** 18(17) : 1831-1851.
- Singla, A. K., Babber, P. and Pathak, K. 1991. Effect of zinc-ion on indomethacin degradation in alkaline aqueous solutions. **Drug Dev. Ind. Pharm.** 17(10) : 1411-1418.
- Sjokvist, E., Nystrom, C. Alden, M. and Lelhan, N.C. 1992. Physicochemical aspects of drug release XIV. The effects of some ionic and non-ionic surfactants on properties of a sparingly soluble drug in solid dispersions. **Int. J. Pharm.** 79 : 123-133.
- Sulieman, M. and Najib, M.N. 1990. Kinetics of alkaline hydrolysis of indomethacin in the presence of surfactants and cosolvents. **Drug Dev. Ind. Pharm.** 16(4) : 695-706.
- Sutananata, W., Craig, D.Q. and Newton, J.M. 1994. The effects of ageing on the thermal behaviour and mechanical properties of pharmaceutical glycerides. **Int. J. Pharm.** 111 : 51-62.
- Synder, I., Kirkland, J. and Glajoh, J. 1997. **Practical HPLC Method Development** 2nd edition. (United Stated of American), p. 50-100.

Szejli, J. **Cyclodextrins and their inclusion complexes.** (Budapest : Akademiai Kado, 1982), p.1-110.

Takenchi, H. and Kawashima, Y. 1987. Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants. **J. Pharm. Pharmac.** 39 : 769-773.

Tasic, L.J., Jovanovic, M.O. and Djuric, Z.R. 1992. The influence of β -cyclodextrin on the solubility and dissolution rate of paracetamol solid dispersion. **J. Pharm. Pharmac.** 44 : 52-55.

Tekenaka, H., Kawashima, Y., Lin, S.Y. and Ando, Y. 1982. Preparations of solid particulates of theophylline-ethylenediamine complex by spray-drying technique. **J. Pharm. Sci.** 71(8) : 914-919.

Tian, Y. and Li, L.C. 1998. Light-scattering method in particle size analysis of parenteral emulsions. **Drug Dev. Ind. Pharm.** 24(3) : 275-280.

Tokumura, T., Ueda, H., Tsushima, Y., Kasai, M., Kayano, M., Amada, I. and Nagai, T. 1984. Inclusion complexes of cinnarizine with β -cyclodextrin in aqueous solution and in the solid state. **Chem. Pharm. Bull.** 32(10) : 4179-4184.

Torricelli, C., Martini, A., Muggetti, L. and Ponti, D.R. 1991. Stability studies on a steroid drug/ β -cyclodextrin coground mixture. **Int. J. Pharm.** 71: 19-24.

Torricelli, C., Martini, A., Muggetti, L., Eli, M. and Ponti, D.R. 1991. Stability studies on steroid drug/ β -cyclodextrin kneaded systems. **Int. J. Pharm.** 75 : 147-153.

Uekema, K., Hirayama, F., Wakuda, T. and Otagiri, M. 1981. Effects of cyclodextrins on the hydrolysis of prostacyclin and its methyl ester in aqueous solution. **Chem. Pharm. Bull.** 29(1) : 213-219.

Veiga, M.O., Bernad, M.J. and Escobar, C. 1993. Thermal behaviour of drugs from binary and ternary systems. **Int. J. Pharm.** 89 : 119-124.

- Viega, F., Teixeira-Dias JJC, Kedzierewicz, F., Sousa, A. and Mainant, P. 1996.
Inclusion complexation of tolbutamide with β -cyclodextrin and hydroxypropyl- β -cyclodextrin. *Int. J. Pharm.* 129 : 63-71.
- Wan, L.S., Heng, P.W. and Chia, C.G. 1991. Preparation of coated particles using a spray drying process with an aqueous system. *Int. J. Pharm.* 77: 183-191.

APPENDICES

APPENDIX A

HPLC VALIDATION

Validation for the quantitative determination of indomethacin by HPLC

1. Accuracy

These experiments were conducted to verify that the methods used for indomethacin analysis in phosphate buffer pH 7.4, in BCD solution and in SLS solution were sufficiently accurate and precise. The calibration curve of standard solutions of IMC for accuracy determination was shown in Figure 8A. The accuracy is calculated from the test results as percentage of analyte recovered by the assay (USP XXIII).

a) Analysis of Indomethacin in pH 7.4 phosphate buffer

Table 1A shows percent analytical recovery at each IMC concentration in phosphate buffer pH 7.4 and Figure 1A shows typical chromatogram of IMC in phosphate buffer pH 7.4. The mean percent analytical recovery was sufficiently high (100.50%) with a low %CV (coefficient of variation, 3.19%), which indicated that HPLC method was accurate for quantitative analysis of IMC in the range of concentration studied.

b) Analysis of indomethacin in phosphate buffer pH 7.4 containing beta cyclodextrin

Figure 2A shows typical chromatogram of IMC in phosphate buffer pH 7.4 containing beta cyclodextrin. The percent analytical recovery of each concentration of IMC with BCD in phosphate buffer pH 7.4 was shown in Table 2A. The results showed that the recovery was sufficiently high (close to 100%), although %CV of the percentage recovery was higher than that obtained from the IMC in phosphate buffer pH 7.4. These results indicated that the satisfactory quantitation of IMC and beta cyclodextrin in phosphate buffer pH 7.4 was achieved by using HPLC. Although accuracy within 2% of actual values is required, accuracy within 10% of the true value is still achievable. There are some errors in any part of HPLC method can

have effect on accuracy such as improper data handling because the reference standard materials are not certified standard. This effect can be reduced by using additional chromatographic methods (such as TLC, GC etc.) to confirm that a single pure compound exists for use as a reference standard (Practical HPLC method development, 1997).

Table 1A Accuracy data of indomethacin in phosphate buffer pH 7.4 analysis

Actual Concentration (mcg/ml)	Analytical Concentration (mcg/ml)	% Recovery
50	48.08	96.16
	48.16	96.32
	48.13	96.26
150	154.82	103.21
	153.66	102.44
	153.39	102.26
350	359.76	102.79
	357.97	102.28
	359.82	102.80
		Mean = 100.50 SD = 3.21
		%CV = 3.19




Figure 1A HPLC chromatograms of indomethacin in phosphate buffer pH 7.4.
[50 mcg/ml,(A); 150 mcg/ml,(B); and 350 mcg/ml,(C)].




Figure 2A HPLC chromatograms of indomethacin in phosphate buffer pH 7.4 containing beta cyclodextrin. [50 mcg/ml, (A); 150 mcg/ml, (B); and 350 mcg/ml, (C)].

Table 2A Accuracy data of indomethacin with beta cyclodextrin in phosphate buffer pH 7.4

Actual Concentration (mcg/ml)	Analytical concentration (mcg/ml)	% Recovery
50.00	46.29	92.58
	45.92	91.84
	45.89	91.79
150.00	149.55	99.70
	149.26	99.51
	148.58	99.05
350.00	353.66	101.05
	352.66	100.76
	357.97	102.28
		Mean = 97.62 SD = 4.27
		%CV = 4.37

c) Analysis of Indomethacin in phosphate buffer pH 7.4 containing sodium lauryl sulfate

Table 3A showed percent analytical recovery of each concentration of IMC in phosphate buffer pH 7.4 containing SLS and Figure 3A showed typical chromatogram of IMC in phosphate buffer pH 7.4 containing sodium lauryl sulfate. All the percentages of analytical recovery of all drug concentrations with a mean of 97.06% and a %CV of 1.92 indicated the high accuracy of this method.

Table 3A Data for accuracy of analysis indomethacin in sodium lauryl sulfate solution

Actual Concentration (mcg/ml)	Analytical Concentration (mcg/ml)	% Recovery
50.00	49.66	99.32
	49.66	99.32
	49.34	98.68
150.00	143.05	95.37
	142.53	95.02
	142.45	94.96
350.00	340.11	97.17
	339.16	96.90
	338.76	96.79
		Mean = 97.06 SD = 1.86
		%CV = 1.92




Figure 3A HPLC chromatograms of indomethacin in phosphate buffer pH 7.4 containing sodium lauryl sulfate. [50 mcg/ml, (A); 150 mcg/ml, (B); and 350 mcg/ml, (C)].

2. Precision

The precision of an analytical method is usually expressed as the standard deviation or relative standard deviation (coefficient of variation). Table 4A and 5A illustrated the data of within run precision, a measure of either degree of reproducibility or repeatability of the analytical method under normal operating conditions in the same day (USP 23), and between run precision, the same as within run precision referred to use of analytical procedure on different days (USP 23), respectively. All coefficient of variation values were in the range of 0.1109-3.6666. This indicated that the HPLC method used were precise for quantitation of IMC concentrations in the range studied. Although the %CV of 1 to 2% may be required, less precise methods (%CV \geq 2%) can be still acceptable. Some errors (such as sample preparation technique etc.) can have an effect on precision. The less precise methods need to be defined accurately by increase the number of replicates performed but it is time-consuming method (Practical HPLC method development, 1997).

3. Specificity

Peak of blank buffer solution and methanol appears in the chromatograms(Figure 4A). Their retention times are 1.45 and 2.63 min, respectively. Figure 7A and 8A shows typical chromatograms of IMC standard solutions where IMC and mefenamic acid were eluted at 10.00-12.00 min and 19.00-21.00 min, respectively.

Figure 5A showed typical chromatograms of IMC in the phosphate buffer pH 9.0 to induce degradation. Indomethacin in this buffer eluted as two distinct peaks with a retention time of 2.31 and 4.04 min, respectively. These peaks did not interfere with other peaks and were assumed to be peaks of degradation products. It indicated that the degradation product peaks were eluted before indomethacin peak. Thus, this method could be used for the analysis of IMC in phosphate buffer pH 7.4 when solubilized in BCD or in SLS, in the presence of its degradation products and it was not interfered by the buffer components.

Table 4A Within run precision data

Concentration (mcg/ml)	Peak Area Ratio			Mean	SD	%CV
	n1	n2	n3			
50.00	0.2267	0.2272	0.2270	0.2270	0.0003	0.1109
100.00	0.4523	0.4524	0.4506	0.4518	0.0010	0.2239
150.00	0.6730	0.6704	0.6684	0.6706	0.0023	0.3439
250.00	1.0997	1.0980	1.0965	1.0981	0.0016	0.1458
350.00	1.4757	1.4749	1.4696	1.4734	0.0033	0.2250

Table 5A Between run precision data

Concentration (mcg/ml)	Peak Area Ratio			Mean	SD	%CV
	Day 1	Day 2	Day 3			
50.00	0.2395	0.2270	0.2235	0.2300	0.0084	3.6571
100.00	0.4445	0.4518	0.4446	0.4470	0.0042	0.9366
150.00	0.6495	0.6706	0.6512	0.6571	0.0117	1.7839
250.00	1.0595	1.0981	1.0413	1.0663	0.0290	2.7201
350.00	1.4695	1.4734	1.3800	1.4410	0.0528	3.6666





Figure 4A HPLC chromatograms of methanol and blank buffer solution pH 7.4.




Figure 5A HPLC chromatogram of decomposed drug solutions in phosphate buffer pH 9.0.

4. Linearity

The linearity is usually expressed in terms of the variance around the slope of the regression line calculated according to an established mathematical relationship from test results obtained by the analysis of samples with varying concentrations of analyte (Huttmann, 1998). Data for the calibration curve of indomethacin in phosphate buffer pH 7.4 are presented in Table 6A. The calibration curve and the HPLC chromatograms of the standard solutions are shown in Figure 8A, 6A and 7A, respectively. Figure 8A shows that the relationship between peak area ratios and indomethacin concentration is linear with correlation coefficient (r) value of 0.9963. These results indicated that the HPLC method was acceptable for quantitative analysis of indomethacin solutions in the range studied.

Table 6A Data for a calibration curve of standard solutions of indomethacin

Actual concentration (mcg/ml)	Peak Area Ratio	Analytical concentration (mcg/ml)	%Recovery
50.00	0.2273	47.63	95.26
100.00	0.4093	95.53	95.53
150.00	0.6206	151.13	100.75
200.00	0.8828	220.13	110.07
250.00	1.0070	252.82	101.13
300.00	1.1507	290.63	96.88
350.00	1.3932	354.45	101.27




Figure 6A HPLC chromatograms of standard solutions of indomethacin. [50 mcg/ml, (A); 100 mcg/ml, (B); 150 mcg/ml, (C); and 200 mcg/ml, (D)]; retention time of indomethacin and mefenamic acid are at 10.00-12.00 and 19.00-21.00 min, respectively].





Figure 7A HPLC chromatograms of standard solutions of indomethacin. [250 mcg/ml, (A); 300 mcg/ml, (B) and 350 mcg/ml, (C); retention time of indomethacin and mefenamic acid are at 10.00-12.00 and 19.00-21.00 min, respectively].



$$y = 0.0038x + 0.0463$$

$$r^2 = 0.9927$$

Where

y = Peak Area Ratio

x = Indomethacin concentration (mcg/ml)

Figure 8A A representation of calibration curve of standard solutions of indomethacin

APPENDIX B

CALIBRATION CURVE DATA

Table 1B UV absorbance data of IMC in phosphate buffer pH 7.4 at 319 nm

Concentration (mcg/ml)	Absorbance
0	0
10	0.196
15	0.297
20	0.39
25	0.486
30	0.588




Figure 1B Standard curve of IMC in pH 7.4 phosphate buffer at 319 nm,
Slope = 0.0196 mcg/ml correlation coefficient = 0.9999

APPENDIX C

PARTICLE SIZE DETERMINATION

Table 1C Particle size distribution of Indomethacin

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.11	0.11	38.38	3.23	21.09
0.62	0.20	0.31	44.72	3.64	24.73
0.72	0.28	0.59	52.10	4.07	28.79
0.84	0.29	0.88	60.69	4.54	33.34
0.98	0.30	1.18	70.71	5.07	38.40
1.15	0.28	1.46	82.37	5.62	44.02
1.34	0.25	1.71	95.97	6.19	50.21
1.56	0.21	1.92	111.80	6.72	56.93
1.81	0.17	2.09	130.25	7.20	64.13
2.11	0.13	2.23	151.73	7.63	71.76
2.46	0.10	2.33	176.77	7.44	79.20
2.86	0.09	2.42	205.94	6.77	85.97
3.34	0.09	2.51	239.92	5.67	91.65
3.88	0.10	2.61	279.50	4.26	95.91
4.52	0.13	2.74	325.62	2.79	98.69
5.27	0.17	2.91	379.35	1.31	100.00
6.14	0.23	3.14	441.94	0.00	100.00
7.15	0.30	3.44	514.86	0.00	100.00
8.34	0.40	3.84	599.81	0.00	100.00
9.71	0.53	4.38	698.78	0.00	100.00
11.31	0.71	5.08	814.08	0.00	100.00
13.18	0.92	6.00			
15.35	1.17	7.17			
17.89	1.46	8.62			
20.84	1.78	10.40			
24.27	2.12	12.52			
28.28	2.48	15.01			
32.95	2.85	17.86			

Table 2C Particle size distribution of II10B130

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.00	0.00	44.72	10.17	64.78
0.62	0.00	0.00	52.10	9.66	74.44
0.72	0.00	0.00	60.69	8.17	82.61
0.84	0.00	0.00	70.71	6.50	89.11
0.98	0.00	0.00	82.37	4.87	93.99
1.15	0.00	0.00	95.97	3.38	97.37
1.34	0.00	0.00	111.80	1.99	99.36
1.56	0.00	0.00	130.25	0.61	99.97
1.81	0.00	0.00	151.73	0.03	100.00
2.11	0.00	0.00	176.77	0.00	100.00
2.46	0.00	0.00	205.94	0.00	100.00
2.86	0.00	0.00	239.92	0.00	100.00
3.34	0.00	0.00	279.50	0.00	100.00
3.88	0.00	0.00	325.62	0.00	100.00
4.52	0.00	0.00	379.35	0.00	100.00
5.27	0.00	0.00	441.94	0.00	100.00
6.14	0.00	0.00	514.86	0.00	100.00
7.15	0.18	0.18	599.81	0.00	100.00
8.34	0.31	0.49	698.78	0.00	100.00
9.71	0.61	1.10	814.08	0.00	100.00
11.31	1.13	2.23			
13.18	1.90	4.13			
15.35	2.99	7.12			
17.89	4.38	11.50			
20.84	6.00	17.50			
24.27	7.65	25.15			
28.28	9.08	34.24			
32.95	10.02	44.26			
38.38	10.36	54.62			




Figure 1C Particle size distribution of indomethacin




Figure 2C Particle size distribution of II10B130

Table 3C Particle size distribution of II10B140

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.14	0.14	44.72	10.11	58.54
0.62	0.26	0.39	52.10	9.90	68.43
0.72	0.33	0.72	60.69	8.74	77.17
0.84	0.33	1.05	70.71	7.08	84.25
0.98	0.31	1.37	82.37	5.42	89.67
1.15	0.28	1.66	95.97	3.96	93.63
1.34	0.24	1.91	111.80	2.78	96.41
1.56	0.20	2.12	130.25	1.82	98.22
1.81	0.17	2.30	151.73	1.02	99.24
2.11	0.15	2.45	176.77	0.51	99.75
2.46	0.14	2.59	205.94	0.21	99.96
2.86	0.15	2.74	239.92	0.04	100.00
3.34	0.15	2.89	279.50	0.00	100.00
3.88	0.15	3.04	325.62	0.00	100.00
4.52	0.14	3.18	379.35	0.00	100.00
5.27	0.12	3.30	441.94	0.00	100.00
6.14	0.11	3.40	514.86	0.00	100.00
7.15	0.10	3.50	599.81	0.00	100.00
8.34	0.19	3.69	698.78	0.00	100.00
9.71	0.35	4.04	814.08	0.00	100.00
11.31	0.67	4.71			
13.18	1.19	5.90			
15.35	1.99	7.90			
17.89	3.09	10.98			
20.84	4.50	15.49			
24.27	6.13	21.62			
28.28	7.77	29.39			
32.95	9.12	38.51			
38.38	9.91	48.42			

Table 4C Particle size distribution of II10B150

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.10	0.10	44.72	10.99	58.57
0.62	0.18	0.28	52.10	10.30	68.87
0.72	0.25	0.53	60.69	8.67	77.54
0.84	0.26	0.80	70.71	6.85	84.39
0.98	0.27	1.07	82.37	5.13	89.52
1.15	0.27	1.34	95.97	3.62	93.14
1.34	0.25	1.59	111.80	2.41	95.56
1.56	0.24	1.82	130.25	1.56	97.11
1.81	0.22	2.04	151.73	0.96	98.07
2.11	0.22	2.26	176.77	0.65	98.73
2.46	0.23	2.49	205.94	0.42	99.15
2.86	0.26	2.75	239.92	0.50	99.64
3.34	0.30	3.05	279.50	0.17	99.81
3.88	0.33	3.39	325.62	0.12	99.93
4.52	0.36	3.75	379.35	0.07	100.00
5.27	0.34	4.09	441.94	0.00	100.00
6.14	0.29	4.38	514.86	0.00	100.00
7.15	0.23	4.62	599.81	0.00	100.00
8.34	0.22	4.83	698.78	0.00	100.00
9.71	0.29	5.12	814.08	0.00	100.00
11.31	0.50	5.62			
13.18	0.91	6.53			
15.35	1.57	8.10			
17.89	2.52	10.62			
20.84	3.82	14.45			
24.27	5.51	19.95			
28.28	7.48	27.44			
32.95	9.42	36.86			
38.38	10.73	47.59			




Figure 3C Particle size distribution of II10B140




Figure 4C Particle size distribution of II10B150

Table 5C Particle size distribution of II15B130

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.07	0.07	44.72	6.86	32.53
0.62	0.12	0.19	52.10	7.80	40.33
0.72	0.17	0.36	60.69	8.39	48.71
0.84	0.19	0.55	70.71	8.51	57.23
0.98	0.20	0.76	82.37	8.23	65.46
1.15	0.20	0.95	95.97	7.71	73.17
1.34	0.19	1.14	111.80	6.48	79.65
1.56	0.16	1.31	130.25	5.28	84.93
1.81	0.14	1.45	151.73	4.12	89.05
2.11	0.11	1.55	176.77	3.18	92.23
2.46	0.09	1.64	205.94	2.46	94.69
2.86	0.08	1.73	239.92	1.91	96.60
3.34	0.09	1.81	279.50	1.44	98.04
3.88	0.11	1.92	325.62	1.02	99.07
4.52	0.16	2.08	379.35	0.60	99.67
5.27	0.21	2.29	441.94	0.22	99.89
6.14	0.27	2.56	514.86	0.11	100.00
7.15	0.35	2.91	599.81	0.00	100.00
8.34	0.42	3.33	698.78	0.00	100.00
9.71	0.51	3.85	814.08	0.00	100.00
11.31	0.62	4.47			
13.18	0.78	5.24			
15.35	1.01	6.25			
17.89	1.35	7.61			
20.84	1.85	9.46			
24.27	2.54	12.00			
28.28	3.44	15.44			
32.95	4.52	19.96			
38.38	5.71	25.67			

Table 6C Particle size distribution of II15B140

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.06	0.06	44.72	6.92	41.99
0.62	0.12	0.19	52.10	7.32	49.31
0.72	0.17	0.36	60.69	7.47	56.78
0.84	0.20	0.55	70.71	7.35	64.12
0.98	0.21	0.77	82.37	7.02	71.14
1.15	0.22	0.99	95.97	6.20	77.34
1.34	0.22	1.20	111.80	5.16	82.50
1.56	0.21	1.41	130.25	4.19	86.69
1.81	0.19	1.60	151.73	3.38	90.07
2.11	0.16	1.76	176.77	2.80	92.88
2.46	0.14	1.91	205.94	2.37	95.25
2.86	0.13	2.04	239.92	1.99	97.24
3.34	0.12	2.17	279.50	1.52	98.75
3.88	0.13	2.30	325.62	0.92	99.68
4.52	0.15	2.45	379.35	0.32	100.00
5.27	0.19	2.64	441.94	0.00	100.00
6.14	0.25	2.89	514.86	0.00	100.00
7.15	0.35	3.24	599.81	0.00	100.00
8.34	0.50	3.75	698.78	0.00	100.00
9.71	0.72	4.47	814.08	0.00	100.00
11.31	1.01	5.49			
13.18	1.40	6.89			
15.35	1.89	8.79			
17.89	2.50	11.28			
20.84	3.18	14.46			
24.27	3.95	18.41			
28.28	4.76	23.17			
32.95	5.57	28.74			
38.38	6.32	34.06			




Figure 5C Particle size distribution of II15B130




Figure 6C Particle size distribution of II15B140

Table 7C Particle size distribution of II15B150

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.11	0.11	44.72	8.10	64.14
0.62	0.21	0.32	52.10	7.59	71.73
0.72	0.29	0.61	60.69	6.94	78.67
0.84	0.33	0.94	70.71	5.85	84.52
0.98	0.36	1.30	82.37	4.73	89.25
1.15	0.37	1.67	95.97	3.66	92.92
1.34	0.38	2.05	111.80	2.71	95.63
1.56	0.37	2.42	130.25	1.91	97.54
1.81	0.35	2.78	151.73	1.23	98.77
2.11	0.34	3.12	176.77	0.69	99.46
2.46	0.33	3.45	205.94	0.35	99.82
2.86	0.33	3.78	239.92	0.14	99.95
3.34	0.34	4.12	279.50	0.05	100.00
3.88	0.35	4.47	325.62	0.00	99.92
4.52	0.38	4.85	379.35	0.00	100.00
5.27	0.41	5.25	441.94	0.00	100.00
6.14	0.46	5.71	514.86	0.00	100.00
7.15	0.57	6.28	599.81	0.00	100.00
8.34	0.77	7.05	698.78	0.00	100.00
9.71	1.09	8.14	814.08	0.00	100.00
11.31	1.59	9.73			
13.18	2.29	12.01			
15.35	3.21	15.22			
17.89	4.33	19.56			
20.84	5.55	25.11			
24.27	6.73	31.84			
28.28	7.65	39.49			
32.95	8.21	47.70			
38.38	8.34	56.04			

Table 8C Particle size distribution of II20B130

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.06	0.06	44.72	9.23	53.07
0.62	0.12	0.18	52.10	9.19	62.26
0.72	0.17	0.35	60.69	8.91	71.17
0.84	0.19	0.54	70.71	7.64	78.82
0.98	0.21	0.75	82.37	6.15	84.97
1.15	0.22	0.97	95.97	4.64	89.61
1.34	0.22	1.20	111.80	3.28	92.89
1.56	0.22	1.42	130.25	2.19	95.08
1.81	0.21	1.63	151.73	1.36	96.44
2.11	0.20	1.83	176.77	0.83	97.27
2.46	0.19	2.03	205.94	0.55	97.82
2.86	0.19	2.21	239.92	0.44	98.26
3.34	0.18	2.39	279.50	0.41	98.67
3.88	0.16	2.55	325.62	0.41	99.08
4.52	0.15	2.70	379.35	0.36	99.44
5.27	0.13	2.82	441.94	0.29	99.73
6.14	0.12	2.94	514.86	0.19	99.92
7.15	0.14	3.09	599.81	0.07	99.99
8.34	0.22	3.31	698.78	0.01	100.00
9.71	0.40	3.71	814.08	0.00	100.00
11.31	0.70	4.41			
13.18	1.20	5.61			
15.35	1.92	7.53			
17.89	2.90	10.43			
20.84	4.12	14.55			
24.27	5.48	20.04			
28.28	6.87	26.90			
32.95	8.06	34.96			
38.38	8.88	43.84			




Figure 7C Particle size distribution of II15B150




Figure 8C Particle size distribution of II20B130

Table 9C Particle size distribution of II20B140

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.09	0.09	44.72	9.56	56.73
0.62	0.17	0.26	52.10	9.06	65.79
0.72	0.24	0.51	60.69	7.96	73.74
0.84	0.27	0.79	70.71	6.22	79.97
0.98	0.30	1.08	82.37	4.55	84.52
1.15	0.31	1.39	95.97	3.12	87.64
1.34	0.30	1.69	111.80	2.04	89.68
1.56	0.29	1.98	130.25	1.36	91.05
1.81	0.27	2.25	151.73	1.00	92.05
2.11	0.25	2.50	176.77	0.90	92.95
2.46	0.22	2.72	205.94	0.95	93.90
2.86	0.21	2.92	239.92	1.05	94.95
3.34	0.19	3.12	279.50	1.10	96.05
3.88	0.18	3.30	325.62	1.07	97.12
4.52	0.16	3.45	379.35	0.95	98.07
5.27	0.13	3.59	441.94	0.77	98.83
6.14	0.12	3.70	514.86	0.58	99.41
7.15	0.13	3.83	599.81	0.38	99.79
8.34	0.20	4.03	698.78	0.19	99.98
9.71	0.37	4.40	814.08	0.02	100.00
11.31	0.68	5.08			
13.18	1.19	6.27			
15.35	1.95	8.22			
17.89	3.00	11.22			
20.84	4.32	15.54			
24.27	5.86	21.39			
28.28	7.45	28.84			
32.95	8.79	37.63			
38.38	9.54	47.17			

Table 10C Particle size distribution of II20B150

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.1	0.10	44.72	8.54	54.72
0.62	0.19	0.30	52.10	8.56	63.28
0.72	0.27	0.57	60.69	8.39	71.66
0.84	0.29	0.85	70.71	7.38	79.04
0.98	0.29	1.15	82.37	6.15	85.20
1.15	0.29	1.44	95.97	4.86	90.06
1.34	0.26	1.70	111.80	3.64	93.69
1.56	0.23	1.92	130.25	2.58	96.28
1.81	0.19	2.11	151.73	1.71	97.99
2.11	0.15	2.27	176.77	1.06	99.05
2.46	0.14	2.41	205.94	0.60	99.65
2.86	0.14	2.56	239.92	0.21	99.86
3.34	0.17	2.73	279.50	0.08	99.94
3.88	0.22	2.96	325.62	0.05	99.99
4.52	0.29	3.24	379.35	0.01	100.00
5.27	0.37	3.62	441.94	0.00	100.00
6.14	0.47	4.09	514.86	0.00	100.00
7.15	0.59	4.68	599.81	0.00	100.00
8.34	0.74	5.42	698.78	0.00	100.00
9.71	0.95	6.36	814.08	0.00	100.00
11.31	1.25	7.61			
13.18	1.68	9.29			
15.35	2.29	11.57			
17.89	3.10	14.67			
20.84	4.12	18.79			
24.27	5.28	24.07			
28.28	6.45	30.52			
32.95	7.46	37.99			
38.38	8.19	46.17			




Figure 9C Particle size distribution of II20B140




Figure 10C Particle size distribution of II20B150

Table 11C Particle size distribution of I10B130

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.09	0.09	38.38	10.08	49.44
0.62	0.18	0.27	44.72	10.34	59.79
0.72	0.24	0.52	52.10	10.18	69.96
0.84	0.27	0.78	60.69	8.48	78.44
0.98	0.28	1.07	70.71	6.48	84.92
1.15	0.28	1.35	82.37	4.55	89.47
1.34	0.28	1.63	95.97	2.94	92.41
1.56	0.26	1.89	111.80	1.79	94.20
1.81	0.24	2.13	130.25	1.11	95.32
2.11	0.23	2.36	151.73	0.79	96.11
2.46	0.23	2.58	176.77	0.73	96.83
2.86	0.24	2.82	205.94	0.76	97.59
3.34	0.26	3.08	239.92	0.77	98.36
3.88	0.27	3.35	279.50	0.70	99.06
4.52	0.27	3.62	325.62	0.53	99.59
5.27	0.26	3.88	379.35	0.32	99.91
6.14	0.24	4.13	441.94	0.09	100.00
7.15	0.23	4.36	514.86	0.00	100.00
8.34	0.27	4.63	599.81	0.00	100.00
9.71	0.40	5.03	698.78	0.00	100.00
11.31	0.69	5.72	814.08	0.00	100.00
13.18	1.19	6.91			
15.35	1.96	8.87			
17.89	3.04	11.90			
20.84	4.44	16.34			
24.27	6.07	22.42			
28.28	7.76	30.17			
32.95	9.19	39.36			

Table 12C Particle size distribution of I10B140

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.12	0.12	44.72	9.40	59.64
0.62	0.23	0.35	52.10	9.38	69.02
0.72	0.32	0.67	60.69	8.11	77.13
0.84	0.35	1.01	70.71	6.49	83.62
0.98	0.37	1.38	82.37	4.81	88.42
1.15	0.37	1.75	95.97	3.30	91.72
1.34	0.36	2.11	111.80	2.13	93.85
1.56	0.33	2.44	130.25	1.38	95.23
1.81	0.30	2.74	151.73	0.99	96.22
2.11	0.27	3.01	176.77	0.86	97.07
2.46	0.26	3.27	205.94	0.85	97.92
2.86	0.25	3.52	239.92	0.82	98.74
3.34	0.26	3.78	279.50	0.68	99.42
3.88	0.27	4.05	325.62	0.42	99.84
4.52	0.28	4.34	379.35	0.16	100.00
5.27	0.30	4.64	441.94	0.00	100.00
6.14	0.32	4.96	514.86	0.00	100.00
7.15	0.37	5.33	599.81	0.00	100.00
8.34	0.48	5.81	698.78	0.00	100.00
9.71	0.69	6.51	814.08	0.00	100.00
11.31	1.05	7.56			
13.18	1.60	9.16			
15.35	2.37	11.53			
17.89	3.38	14.91			
20.84	4.60	19.51			
24.27	5.95	25.46			
28.28	7.28	32.74			
32.95	8.39	41.13			
38.38	9.11	50.23			




Figure 11C Particle size distribution of I10B130




Figure 12C Particle size distribution of I10B140

Table 13C Particle size distribution of I10B150

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.09	0.09	44.72	10.56	57.28
0.62	0.17	0.26	52.10	10.71	67.99
0.72	0.24	0.49	60.69	9.22	77.21
0.84	0.26	0.75	70.71	7.26	84.47
0.98	0.27	1.02	82.37	5.22	89.68
1.15	0.27	1.29	95.97	3.41	93.09
1.34	0.26	1.55	111.80	2.01	95.10
1.56	0.24	1.79	130.25	1.08	96.18
1.81	0.22	2.01	151.73	0.57	96.74
2.11	0.21	2.22	176.77	0.41	97.15
2.46	0.20	2.42	205.94	0.42	97.57
2.86	0.21	2.63	239.92	0.48	98.05
3.34	0.23	2.86	279.50	0.53	98.57
3.88	0.24	3.11	325.62	0.50	99.07
4.52	0.25	3.36	379.35	0.40	99.47
5.27	0.25	3.61	441.94	0.25	99.72
6.14	0.24	3.85	514.86	0.12	99.84
7.15	0.22	4.07	599.81	0.09	99.92
8.34	0.25	4.32	698.78	0.05	99.98
9.71	0.36	4.68	814.08	0.02	100.00
11.31	0.60	5.28			
13.18	1.04	6.32			
15.35	1.73	8.06			
17.89	2.73	10.79			
20.84	4.06	14.85			
24.27	5.64	20.50			
28.28	7.34	27.84			
32.95	8.89	36.73			
38.38	9.99	46.72			

Table 14C Particle size distribution of I15B130

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.00	0.00	44.72	10.34	65.13
0.62	0.00	0.00	52.10	10.22	75.36
0.72	0.00	0.00	60.69	8.66	84.02
0.84	0.00	0.00	70.71	6.65	90.66
0.98	0.00	0.00	82.37	4.58	95.24
1.15	0.00	0.00	95.97	2.81	98.05
1.34	0.00	0.00	111.80	1.44	99.50
1.56	0.00	0.00	130.25	0.41	99.91
1.81	0.00	0.00	151.73	0.09	100.00
2.11	0.00	0.00	176.77	0.00	100.00
2.46	0.00	0.00	205.94	0.00	100.00
2.86	0.27	0.27	239.92	0.00	100.00
3.34	0.25	0.51	279.50	0.00	100.00
3.88	0.24	0.76	325.62	0.00	100.00
4.52	0.25	1.01	379.35	0.00	100.00
5.27	0.29	1.30	441.94	0.00	100.00
6.14	0.35	1.66	514.86	0.00	100.00
7.15	0.47	2.13	599.81	0.00	100.00
8.34	0.66	2.79	698.78	0.00	100.00
9.71	0.96	3.75	814.08	0.00	100.00
11.31	1.44	5.19			
13.18	2.12	7.31			
15.35	3.02	10.33			
17.89	4.17	14.49			
20.84	5.50	20.00			
24.27	6.94	26.94			
28.28	8.32	35.26			
32.95	9.42	44.69			
38.38	10.11	54.79			




Figure 13C Particle size distribution of I10B150




Figure 14C Particle size distribution of I15B130

Table 15C Particle size distribution of I15B140

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.09	0.09	44.72	9.76	52.76
0.62	0.17	0.27	52.10	9.81	62.57
0.72	0.24	0.51	60.69	9.53	72.10
0.84	0.26	0.77	70.71	7.92	80.01
0.98	0.27	1.04	82.37	6.05	86.06
1.15	0.27	1.31	95.97	4.20	90.26
1.34	0.25	1.56	111.80	2.62	92.88
1.56	0.22	1.78	130.25	1.45	94.33
1.81	0.19	1.96	151.73	0.67	95.00
2.11	0.16	2.12	176.77	0.28	95.29
2.46	0.14	2.27	205.94	0.20	95.49
2.86	0.15	2.42	239.92	0.30	95.79
3.34	0.17	2.59	279.50	0.47	96.26
3.88	0.21	2.79	325.62	0.63	96.89
4.52	0.25	3.04	379.35	0.70	97.59
5.27	0.30	3.34	441.94	0.70	98.30
6.14	0.34	3.68	514.86	0.63	98.93
7.15	0.39	4.07	599.81	0.51	99.44
8.34	0.46	4.53	698.78	0.36	99.80
9.71	0.58	5.11	814.08	0.20	100.00
11.31	0.80	5.92			
13.18	1.17	7.08			
15.35	1.70	8.79			
17.89	2.48	11.26			
20.84	3.51	14.77			
24.27	4.82	19.60			
28.28	6.36	25.96			
32.95	7.92	33.88			
38.38	9.13	43.01			

Table 16C Particle size distribution of I15B150

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.13	0.13	44.72	11.27	64.76
0.62	0.24	0.37	52.10	10.14	74.90
0.72	0.33	0.70	60.69	8.35	83.25
0.84	0.36	1.06	70.71	6.29	89.55
0.98	0.38	1.43	82.37	4.32	93.86
1.15	0.37	1.81	95.97	2.58	96.53
1.34	0.35	2.15	111.80	1.46	97.99
1.56	0.31	2.46	130.25	0.70	98.69
1.81	0.27	2.73	151.73	0.32	99.00
2.11	0.24	2.96	176.77	0.18	99.19
2.46	0.22	3.18	205.94	0.18	99.37
2.86	0.22	3.40	239.92	0.21	99.58
3.34	0.23	3.63	279.50	0.19	99.77
3.88	0.26	3.89	325.62	0.13	99.90
4.52	0.29	4.18	379.35	0.06	99.96
5.27	0.31	4.49	441.94	0.04	100.00
6.14	0.32	4.81	514.86	0.00	100.00
7.15	0.35	5.16	599.81	0.00	100.00
8.34	0.43	5.59	698.78	0.00	100.00
9.71	0.60	6.19	814.08	0.00	100.00
11.31	0.93	7.12			
13.18	1.46	8.58			
15.35	2.25	10.83			
17.89	3.33	14.17			
20.84	4.71	18.88			
24.27	6.34	25.22			
28.28	8.05	33.27			
32.95	9.57	42.84			
38.38	10.64	53.48			




Figure 15C Particle size distribution of I15B140




Figure 16C Particle size distribution of I15B150

Table 17C Particle size distribution of Formulation I20B130

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.08	0.08	44.72	6.85	57.38
0.62	0.15	0.23	52.10	6.56	63.94
0.72	0.21	0.45	60.69	6.12	70.06
0.84	0.24	0.68	70.71	5.59	75.64
0.98	0.25	0.93	82.37	4.88	80.53
1.15	0.26	1.19	95.97	4.19	84.72
1.34	0.25	1.45	111.80	3.54	88.26
1.56	0.24	1.69	130.25	2.97	91.23
1.81	0.22	1.91	151.73	2.44	93.66
2.11	0.21	2.12	176.77	1.95	95.62
2.46	0.20	2.32	205.94	1.51	97.13
2.86	0.21	2.54	239.92	1.11	98.24
3.34	0.23	2.77	279.50	0.75	98.99
3.88	0.27	3.03	325.62	0.44	99.43
4.52	0.33	3.37	379.35	0.27	99.70
5.27	0.42	3.79	441.94	0.15	99.85
6.14	0.57	4.35	514.86	0.13	99.95
7.15	0.77	5.12	599.81	0.05	100.00
8.34	1.06	6.19	698.78	0.00	100.00
9.71	1.46	7.65	814.08	0.00	100.00
11.31	1.99	9.64			
13.18	2.62	12.26			
15.35	3.36	15.62			
17.89	4.16	19.78			
20.84	4.97	24.74			
24.27	5.73	30.47			
28.28	6.36	36.83			
32.95	6.77	43.64			
38.38	6.93	50.53			

Table 18C Particle size distribution of I20B140

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.11	0.11	44.72	8.35	56.32
0.62	0.21	0.33	52.10	8.28	64.61
0.72	0.29	0.62	60.69	8.03	72.63
0.84	0.30	0.92	70.71	6.94	79.57
0.98	0.30	1.23	82.37	5.57	85.23
1.15	0.29	1.52	95.97	4.36	89.59
1.34	0.27	1.79	111.80	3.20	92.79
1.56	0.24	2.03	130.25	2.28	95.06
1.81	0.22	2.25	151.73	1.57	96.63
2.11	0.20	2.45	176.77	1.09	97.71
2.46	0.21	2.66	205.94	0.77	98.48
2.86	0.23	2.89	239.92	0.55	99.03
3.34	0.26	3.15	279.50	0.37	99.40
3.88	0.30	3.44	325.62	0.23	99.63
4.52	0.34	3.78	379.35	0.15	99.78
5.27	0.39	4.17	441.94	0.11	99.89
6.14	0.45	4.62	514.86	0.10	99.96
7.15	0.55	5.16	599.81	0.04	100.00
8.34	0.71	5.87	698.78	0.00	100.00
9.71	0.96	6.83	814.08	0.00	100.00
11.31	1.34	8.18			
13.18	1.87	10.05			
15.35	2.56	12.61			
17.89	3.40	16.00			
20.84	4.39	20.40			
24.27	5.47	25.87			
28.28	6.55	32.42			
32.95	7.47	39.88			
38.38	8.09	47.98			




Figure 17C Particle size distribution of I20B130




Figure 18C Particle size distribution of I20B140

Table 19C Particle size distribution of I20B150

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.11	0.11	44.72	7.69	60.46
0.62	0.21	0.32	52.10	7.18	67.63
0.72	0.28	0.61	60.69	6.51	74.14
0.84	0.30	0.92	70.71	5.32	79.46
0.98	0.32	1.23	82.37	4.13	83.59
1.15	0.31	1.54	95.97	3.09	86.68
1.34	0.30	1.84	111.80	2.28	88.96
1.56	0.27	2.11	130.25	1.74	90.70
1.81	0.25	2.36	151.73	1.40	92.10
2.11	0.23	2.58	176.77	1.24	93.34
2.46	0.22	2.81	205.94	1.16	94.49
2.86	0.23	3.04	239.92	1.10	95.59
3.34	0.25	3.28	279.50	1.02	96.61
3.88	0.27	3.55	325.62	0.90	97.51
4.52	0.30	3.85	379.35	0.74	98.25
5.27	0.35	4.20	441.94	0.58	98.83
6.14	0.43	4.63	514.86	0.42	99.25
7.15	0.57	5.20	599.81	0.31	99.56
8.34	0.80	6.00	698.78	0.27	99.83
9.71	1.15	7.15	814.08	0.17	100.00
11.31	1.67	8.81			
13.18	2.35	11.16			
15.35	3.20	14.35			
17.89	4.18	18.53			
20.84	5.23	23.76			
24.27	6.25	30.01			
28.28	7.13	37.14			
32.95	7.72	44.86			
38.38	7.90	52.77			

Table 20C Particle size distribution of I10BB130

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0	0.00	44.72	11.52	66.38
0.62	0.00	0.00	52.10	11.26	77.64
0.72	0.00	0.00	60.69	9.07	86.71
0.84	0.00	0.00	70.71	6.60	93.32
0.98	0.00	0.00	82.37	4.31	97.62
1.15	0.00	0.00	95.97	2.21	99.83
1.34	0.00	0.00	111.80	0.17	100.00
1.56	0.00	0.00	130.25	0.00	100.00
1.81	0.00	0.00	151.73	0.00	100.00
2.11	0.00	0.00	176.77	0.00	100.00
2.46	0.31	0.31	205.94	0.00	100.00
2.86	0.29	0.60	239.92	0.00	100.00
3.34	0.30	0.90	279.50	0.00	100.00
3.88	0.30	1.20	325.62	0.00	100.00
4.52	0.32	1.52	379.35	0.00	100.00
5.27	0.36	1.88	441.94	0.00	100.00
6.14	0.40	2.27	514.86	0.00	100.00
7.15	0.46	2.74	599.81	0.00	100.00
8.34	0.58	3.31	698.78	0.00	100.00
9.71	0.77	4.09	814.08	0.00	100.00
11.31	1.12	5.21			
13.18	1.67	6.88			
15.35	2.48	9.36			
17.89	3.63	12.99			
20.84	5.10	18.08			
24.27	6.82	24.91			
28.28	8.61	33.51			
32.95	10.16	43.67			
38.38	11.19	54.86			




Figure 19C Particle size distribution of I20B150




Figure 20C Particle size distribution of I10BB130

Table 21C Particle size distribution of I10BB140

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.00	0.00	44.72	9.00	42.41
0.62	0.00	0.00	52.10	9.74	52.15
0.72	0.00	0.00	60.69	10.02	62.17
0.84	0.00	0.00	70.71	9.94	72.11
0.98	0.00	0.00	82.37	8.50	80.61
1.15	0.00	0.00	95.97	6.70	87.31
1.34	0.00	0.00	111.80	4.88	92.19
1.56	0.00	0.00	130.25	3.33	95.53
1.81	0.00	0.00	151.73	2.19	97.71
2.11	0.00	0.00	176.77	1.19	98.90
2.46	0.00	0.00	205.94	0.41	99.31
2.86	0.24	0.24	239.92	0.34	99.65
3.34	0.23	0.47	279.50	0.23	99.88
3.88	0.24	0.71	325.62	0.12	100.00
4.52	0.27	0.98	379.35	0.00	100.00
5.27	0.30	1.28	441.94	0.00	100.00
6.14	0.33	1.61	514.86	0.00	100.00
7.15	0.37	1.98	599.81	0.00	100.00
8.34	0.43	2.41	698.78	0.00	100.00
9.71	0.52	2.92	814.08	0.00	100.00
11.31	0.67	3.59			
13.18	0.92	4.51			
15.35	1.31	5.82			
17.89	1.89	7.70			
20.84	2.69	10.39			
24.27	3.74	14.13			
28.28	5.01	19.14			
32.95	6.43	25.58			
38.38	7.83	33.41			

Table 22C Particle size distribution of I10BB150

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.05	0.05	44.72	7.76	37.63
0.62	0.09	0.14	52.10	8.73	46.35
0.72	0.13	0.27	60.69	9.43	55.79
0.84	0.15	0.41	70.71	9.90	65.68
0.98	0.16	0.57	82.37	8.99	74.67
1.15	0.17	0.74	95.97	7.50	82.17
1.34	0.17	0.90	111.80	5.75	87.92
1.56	0.16	1.06	130.25	4.06	91.99
1.81	0.15	1.22	151.73	2.59	94.57
2.11	0.14	1.36	176.77	1.48	96.06
2.46	0.14	1.50	205.94	0.80	96.85
2.86	0.15	1.65	239.92	0.46	97.31
3.34	0.16	1.81	279.50	0.36	97.67
3.88	0.19	2.00	325.62	0.38	98.05
4.52	0.24	2.24	379.35	0.42	98.48
5.27	0.29	2.52	441.94	0.43	98.91
6.14	0.35	2.87	514.86	0.39	99.30
7.15	0.42	3.29	599.81	0.32	99.62
8.34	0.50	3.78	698.78	0.25	99.86
9.71	0.59	4.37	814.08	0.14	100.00
11.31	0.71	5.09			
13.18	0.90	5.99			
15.35	1.18	7.18			
17.89	1.61	8.78			
20.84	2.21	10.99			
24.27	3.02	14.01			
28.28	4.05	18.06			
32.95	5.27	23.33			
38.38	6.55	29.87			




Figure 21C Particle size distribution of I10BB140




Figure 22C Particle size distribution of I10BB150

Table 23C Particle size distribution of I15BB130

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.06	0.06	44.72	8.70	49.28
0.62	0.11	0.17	52.10	9.28	58.56
0.72	0.15	0.32	60.69	9.67	68.23
0.84	0.17	0.49	70.71	8.85	77.08
0.98	0.19	0.67	82.37	7.45	84.54
1.15	0.19	0.86	95.97	5.71	90.24
1.34	0.19	1.05	111.80	3.90	94.15
1.56	0.18	1.22	130.25	2.30	96.45
1.81	0.17	1.39	151.73	1.02	97.46
2.11	0.16	1.56	176.77	0.17	97.63
2.46	0.17	1.73	205.94	0.00	97.63
2.86	0.18	1.90	239.92	0.00	97.63
3.34	0.20	2.11	279.50	0.02	97.65
3.88	0.24	2.35	325.62	0.10	97.75
4.52	0.29	2.64	379.35	0.25	98.00
5.27	0.36	3.00	441.94	0.36	98.35
6.14	0.44	3.44	514.86	0.41	98.77
7.15	0.55	3.98	599.81	0.45	99.21
8.34	0.69	4.67	698.78	0.45	99.66
9.71	0.87	5.54	814.08	0.34	100.00
11.31	1.13	6.67			
13.18	1.49	8.16			
15.35	1.97	10.13			
17.89	2.60	12.73			
20.84	3.40	16.13			
24.27	4.39	20.51			
28.28	5.53	26.04			
32.95	6.72	32.76			
38.38	7.82	40.59			

Table 24C Particle size distribution of I15B140

Geometric mean (um)	ln%	Under %	Geometric mean (um)	ln%	Under %
0.53	0.07	0.07	44.72	8.86	50.94
0.62	0.13	0.20	52.10	9.30	60.24
0.72	0.18	0.38	60.69	9.51	69.75
0.84	0.20	0.59	70.71	8.54	78.28
0.98	0.22	0.81	82.37	7.12	85.40
1.15	0.23	1.03	95.97	5.46	90.86
1.34	0.22	1.26	111.80	3.80	94.66
1.56	0.21	1.47	130.25	2.36	97.01
1.81	0.20	1.66	151.73	1.24	98.26
2.11	0.18	1.85	176.77	0.52	98.78
2.46	0.18	2.02	205.94	0.16	98.94
2.86	0.19	2.21	239.92	0.08	99.02
3.34	0.21	2.42	279.50	0.13	99.16
3.88	0.24	2.66	325.62	0.21	99.36
4.52	0.29	2.95	379.35	0.23	99.60
5.27	0.36	3.32	441.94	0.19	99.78
6.14	0.44	3.76	514.86	0.11	99.89
7.15	0.55	4.31	599.81	0.06	99.95
8.34	0.68	4.99	698.78	0.03	99.98
9.71	0.88	5.87	814.08	0.02	100.00
11.31	1.14	7.01			
13.18	1.51	8.52			
15.35	2.01	10.54			
17.89	2.68	13.21			
20.84	3.53	16.74			
24.27	4.56	21.30			
28.28	5.74	27.04			
32.95	6.97	34.01			
38.38	8.06	42.08			




Figure 23C Particle size distribution of I15BB130




Figure 24C Particle size distribution of I15BB140

Table 25C Particle size distribution of I15B150

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.07	0.07	44.72	9.36	55.78
0.62	0.13	0.19	52.10	9.57	65.35
0.72	0.18	0.37	60.69	8.85	74.20
0.84	0.19	0.57	70.71	7.46	81.66
0.98	0.21	0.77	82.37	5.84	87.50
1.15	0.21	0.99	95.97	4.24	91.74
1.34	0.21	1.19	111.80	2.86	94.60
1.56	0.20	1.39	130.25	1.82	96.42
1.81	0.19	1.58	151.73	1.13	97.55
2.11	0.18	1.76	176.77	0.73	98.28
2.46	0.19	1.95	205.94	0.55	98.83
2.86	0.20	2.15	239.92	0.45	99.28
3.34	0.23	2.38	279.50	0.36	99.64
3.88	0.26	2.65	325.62	0.24	99.87
4.52	0.31	2.95	379.35	0.09	99.96
5.27	0.35	3.31	441.94	0.03	99.99
6.14	0.41	3.72	514.86	0.01	100.00
7.15	0.49	4.21	599.81	0.00	100.00
8.34	0.62	4.83	698.78	0.00	100.00
9.71	0.82	5.65	814.08	0.00	100.00
11.31	1.13	6.78			
13.18	1.59	8.37			
15.35	2.23	10.59			
17.89	3.07	13.66			
20.84	4.11	17.76			
24.27	5.32	23.09			
28.28	6.64	29.73			
32.95	7.87	37.61			
38.38	8.82	46.42			

Table 26C Particle size distribution of I20BB130

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.05	0.05	44.72	7.66	39.49
0.62	0.10	0.15	52.10	8.41	47.90
0.72	0.14	0.29	60.69	8.89	56.79
0.84	0.17	0.47	70.71	9.17	65.96
0.98	0.20	0.67	82.37	8.36	74.33
1.15	0.22	0.89	95.97	7.09	81.42
1.34	0.23	1.13	111.80	5.60	87.02
1.56	0.23	1.37	130.25	4.14	91.16
1.81	0.23	1.59	151.73	2.84	94.00
2.11	0.21	1.80	176.77	1.83	95.83
2.46	0.19	2.00	205.94	1.15	96.98
2.86	0.18	2.17	239.92	0.77	97.75
3.34	0.16	2.34	279.50	0.57	98.33
3.88	0.16	2.50	325.62	0.45	98.78
4.52	0.18	2.68	379.35	0.34	99.12
5.27	0.21	2.89	441.94	0.30	99.42
6.14	0.25	3.14	514.86	0.27	99.66
7.15	0.32	3.45	599.81	0.16	99.82
8.34	0.41	3.87	698.78	0.12	99.93
9.71	0.54	4.41	814.08	0.07	100.00
11.31	0.73	5.14			
13.18	1.00	6.14			
15.35	1.36	7.51			
17.89	1.86	9.37			
20.84	2.52	11.89			
24.27	3.36	15.24			
28.28	4.38	19.63			
32.95	5.53	25.16			
38.38	6.67	31.83			




Figure 25C Particle size distribution of I15BB150




Figure 26C Particle size distribution of I20BB130

Table 27C Particle size distribution of I20BB140

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.09	0.09	44.72	8.15	53.28
0.62	0.17	0.26	52.10	8.36	61.64
0.72	0.25	0.51	60.69	8.40	70.04
0.84	0.28	0.79	70.71	7.49	77.53
0.98	0.31	1.10	82.37	6.25	83.78
1.15	0.32	1.42	95.97	4.88	88.66
1.34	0.32	1.74	111.80	3.57	92.23
1.56	0.30	2.05	130.25	2.47	94.70
1.81	0.28	2.32	151.73	1.63	96.33
2.11	0.25	2.57	176.77	1.09	97.43
2.46	0.22	2.80	205.94	0.78	98.20
2.86	0.21	3.01	239.92	0.62	98.82
3.34	0.21	3.22	279.50	0.49	99.31
3.88	0.23	3.46	325.62	0.37	99.68
4.52	0.28	3.74	379.35	0.23	99.91
5.27	0.35	4.09	441.94	0.09	100.00
6.14	0.46	4.55	514.86	0.00	100.00
7.15	0.61	5.16	599.81	0.00	100.00
8.34	0.81	5.98	698.78	0.00	100.00
9.71	1.09	7.06	814.08	0.00	100.00
11.31	1.44	8.51			
13.18	1.89	10.40			
15.35	2.45	12.85			
17.89	3.13	15.99			
20.84	3.95	19.93			
24.27	4.87	24.80			
28.28	5.87	30.66			
32.95	6.84	37.50			
38.38	7.63	45.13			

Table 28C Particle size distribution of I20BB150

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.11	0.11	44.72	7.11	39.88
0.62	0.21	0.32	52.10	7.89	47.76
0.72	0.29	0.61	60.69	8.44	56.20
0.84	0.31	0.91	70.71	8.79	64.99
0.98	0.32	1.23	82.37	8.35	73.34
1.15	0.32	1.55	95.97	7.24	80.58
1.34	0.29	1.85	111.80	5.83	86.41
1.56	0.26	2.10	130.25	4.34	90.75
1.81	0.22	2.33	151.73	2.97	93.72
2.11	0.19	2.51	176.77	1.89	95.62
2.46	0.17	2.69	205.94	1.17	96.78
2.86	0.18	2.87	239.92	0.75	97.54
3.34	0.20	3.07	279.50	0.58	98.11
3.88	0.25	3.32	325.62	0.51	98.62
4.52	0.31	3.63	379.35	0.46	99.08
5.27	0.39	4.03	441.94	0.38	99.47
6.14	0.48	4.51	514.86	0.28	99.75
7.15	0.57	5.07	599.81	0.18	99.93
8.34	0.67	5.74	698.78	0.07	100.00
9.71	0.78	6.52	814.08	0.00	100.00
11.31	0.93	7.45			
13.18	1.13	8.59			
15.35	1.43	10.01			
17.89	1.85	11.86			
20.84	2.42	14.28			
24.27	3.17	17.45			
28.28	4.07	21.53			
32.95	5.09	26.62			
38.38	6.14	32.76			




Figure 27C Particle size distribution of I20BB140




Figure 28C Particle size distribution of I20BB150

Table 29C Particle size distribution of IS13

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.20	0.20	44.72	4.26	84.64
0.62	0.39	0.60	52.10	2.97	87.62
0.72	0.55	1.15	60.69	2.01	89.62
0.84	0.60	1.74	70.71	1.36	90.99
0.98	0.63	2.38	82.37	1.02	92.01
1.15	0.63	3.01	95.97	0.90	92.91
1.34	0.59	3.60	111.80	0.90	93.81
1.56	0.51	4.11	130.25	0.93	94.74
1.81	0.42	4.53	151.73	0.94	95.68
2.11	0.33	4.86	176.77	0.90	96.57
2.46	0.25	5.11	205.94	0.81	97.39
2.86	0.20	5.31	239.92	0.71	98.09
3.34	0.19	5.50	279.50	0.59	98.68
3.88	0.23	5.74	325.62	0.48	99.16
4.52	0.37	6.10	379.35	0.36	99.52
5.27	0.61	6.72	441.94	0.25	99.76
6.14	1.02	7.74	514.86	0.17	100.00
7.15	1.61	9.34	599.81	0.06	100.00
8.34	2.41	11.76	698.78	0.00	100.00
9.71	3.45	15.21	814.08	0.00	100.00
11.31	4.72	19.93			
13.18	6.10	26.03			
15.35	7.38	33.41			
17.89	8.32	41.74			
20.84	8.75	50.49			
24.27	8.67	59.16			
28.28	8.23	67.39			
32.95	7.26	74.65			
38.38	5.74	80.39			

Table 30C Particle size distribution of IS20

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.33	0.33	44.72	4.07	86.86
0.62	0.62	0.94	52.10	2.82	89.67
0.72	0.82	1.77	60.69	1.81	91.48
0.84	0.85	2.62	70.71	1.08	92.56
0.98	0.84	3.46	82.37	0.64	93.20
1.15	0.79	4.25	95.97	0.42	93.62
1.34	0.68	4.93	111.80	0.37	93.98
1.56	0.55	5.48	130.25	0.40	94.39
1.81	0.43	5.91	151.73	0.46	94.86
2.11	0.33	6.24	176.77	0.53	95.39
2.46	0.27	6.51	205.94	0.58	95.97
2.86	0.26	6.76	239.92	0.62	96.59
3.34	0.30	7.06	279.50	0.64	97.23
3.88	0.39	7.44	325.62	0.63	97.86
4.52	0.58	8.03	379.35	0.59	98.45
5.27	0.89	8.91	441.94	0.52	98.97
6.14	1.33	10.25	514.86	0.43	99.40
7.15	1.94	12.19	599.81	0.32	99.72
8.34	2.75	14.94	698.78	0.20	99.93
9.71	3.76	18.70	814.08	0.07	100.00
11.31	4.98	23.68			
13.18	6.26	29.94			
15.35	7.41	37.35			
17.89	8.19	45.53			
20.84	8.48	54.01			
24.27	8.38	62.39			
28.28	8.07	70.45			
32.95	6.86	77.32			
38.38	5.47	82.78			




Figure 29C Particle size distribution of IS13




Figure 30C Particle size distribution of IS20

Table 31C Particle size distribution of IS27

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.22	0.22	44.72	5.88	89.10
0.62	0.40	0.62	52.10	4.21	93.31
0.72	0.52	1.13	60.69	2.79	96.09
0.84	0.50	1.63	70.71	1.67	97.76
0.98	0.47	2.10	82.37	0.98	98.74
1.15	0.41	2.51	95.97	0.59	99.33
1.34	0.35	2.87	111.80	0.38	99.71
1.56	0.30	3.16	130.25	0.22	99.93
1.81	0.26	3.42	151.73	0.07	100.00
2.11	0.25	3.67	176.77	0.00	100.00
2.46	0.27	3.94	205.94	0.00	100.00
2.86	0.32	4.27	239.92	0.00	100.00
3.34	0.37	4.64	279.50	0.00	100.00
3.88	0.42	5.06	325.62	0.00	100.00
4.52	0.48	5.54	379.35	0.00	100.00
5.27	0.60	6.14	441.94	0.00	100.00
6.14	0.81	6.95	514.86	0.00	100.00
7.15	1.17	8.12	599.81	0.00	100.00
8.34	1.74	9.86	698.78	0.00	100.00
9.71	2.60	12.45	814.08	0.00	100.00
11.31	3.81	16.26			
13.18	5.34	21.60			
15.35	7.02	28.62			
17.89	8.53	37.15			
20.84	9.60	46.75			
24.27	10.02	56.77			
28.28	9.78	66.56			
32.95	9.02	75.58			
38.38	7.63	83.21			

Table 32C Particle size distribution of IS33

Geometric mean diameter (um)	In%	Under size%	Geometric mean diameter (um)	In%	Under size%
0.53	0.25	0.25	44.72	8.89	74.30
0.62	0.43	0.68	52.10	7.36	81.66
0.72	0.50	1.18	60.69	5.64	87.30
0.84	0.39	1.57	70.71	3.97	91.28
0.98	0.28	1.85	82.37	2.56	93.84
1.15	0.18	2.03	95.97	1.52	95.36
1.34	0.10	2.14	111.80	0.90	96.27
1.56	0.05	2.19	130.25	0.87	97.13
1.81	0.02	2.21	151.73	0.75	97.88
2.11	0.14	2.35	176.77	0.73	98.61
2.46	0.17	2.52	205.94	0.64	99.25
2.86	0.22	2.74	239.92	0.45	99.70
3.34	0.28	3.02	279.50	0.23	99.93
3.88	0.31	3.33	325.62	0.07	100.00
4.52	0.33	3.66	379.35	0.00	100.00
5.27	0.34	4.00	441.94	0.00	100.00
6.14	0.38	4.37	514.86	0.00	100.00
7.15	0.49	4.86	599.81	0.00	100.00
8.34	0.74	5.60	698.78	0.00	100.00
9.71	1.18	6.78	814.08	0.00	100.00
11.31	1.89	8.67			
13.18	2.89	11.56			
15.35	4.19	15.74			
17.89	5.67	21.41			
20.84	7.14	28.55			
24.27	8.39	36.94			
28.28	9.26	46.20			
32.95	9.64	55.84			
38.38	9.58	65.42			




Figure 31C Particle size distribution of IS27




Figure 32C Particle size distribution of IS33

Table 33C Particle size distribution of Spray dried Indomethacin

Geometric mean (um)	In%	Under %	Geometric mean (um)	In%	Under %
0.53	0.09	0.09	44.72	6.87	43.43
0.62	0.17	0.26	52.10	7.21	50.65
0.72	0.23	0.49	60.69	7.30	57.95
0.84	0.25	0.74	70.71	7.14	65.09
0.98	0.26	1.01	82.37	6.82	71.91
1.15	0.27	1.27	95.97	5.87	77.78
1.34	0.25	1.53	111.80	4.81	82.59
1.56	0.23	1.76	130.25	3.78	86.37
1.81	0.21	1.97	151.73	2.82	89.19
2.11	0.20	2.17	176.77	2.03	91.22
2.46	0.19	2.36	205.94	1.44	92.66
2.86	0.19	2.54	239.92	1.05	93.71
3.34	0.20	2.74	279.50	0.85	94.56
3.88	0.22	2.97	325.62	0.67	95.23
4.52	0.25	3.22	379.35	0.74	95.98
5.27	0.31	3.52	441.94	0.84	96.82
6.14	0.38	3.91	514.86	0.93	97.75
7.15	0.49	4.39	599.81	0.94	98.70
8.34	0.63	5.02	698.78	0.81	99.51
9.71	0.83	5.85	814.08	0.49	100.00
11.31	1.11	6.96			
13.18	1.47	8.42			
15.35	1.93	10.35			
17.89	2.50	12.86			
20.84	3.17	16.03			
24.27	3.93	19.96			
28.28	4.75	24.71			
32.95	5.56	30.26			
38.38	6.30	36.56			




Figure 33C Particle size distribution of spray dried indomethacin

APPENDICES D

**TGA THERMOGRAMS OF SPRAY DRIED INDOMETHACIN
AND BETA CYCLODEXTRIN**




Figure 1D TGA thermograms of II B prepared by spray drying method, feed rate 10 ml/min [(A) II10B130; (B) II10B140 and (C) II10B150]




Figure 2D TGA thermograms of II B prepared by spray drying method, feed rate 15 ml/min [(A) II15B130; (B) II15B140 and (C) II15B150]




Figure 3D TGA thermograms of II B prepared by spray drying method, feed rate 20 ml/min [(A) II20B130; (B) II20B140 and (C) II20B150]




Figure 4D TGA thermograms of IB prepared by spray drying method, feed rate 10 ml/min
[(A) I10B130; (B) I10B140 and (C) I10B150]

Heat Flow Endo Up (mW)




Figure 5D TGA thermograms of IB prepared by spray drying method, feed rate 20 ml/min
[(A) I15B130; (B) I15B140 and (C) I15B150]




Figure 6D TGA thermograms of IBB prepared by spray drying method, feed rate 10 ml/min [(A) I10BB130; (B) I10BB140 and (C) I10BB150]




Figure 7D TGA thermograms of IBB prepared by spray drying method, feed rate 15 ml/min [(A) I15BB130; (B) I15BB140 and (C) I15BB150]




Figure 8D TGA thermograms of IBB prepared by spray drying method, feed rate 20 ml/min [(A) I20BB130; (B) I20BB140 and (C) I20BB150]

APPENDICES E

**X-RAY DIFFRACTOGRAMS OF SPRAY DRIED INDOMETHACIN
AND BETA CYCLODEXTRIN**




Figure 1E X-ray powder diffractograms of IIB prepared by spray drying method, feed rate 10 ml/min [(A) II10B130; (B) II10B140 and (C) II10B150]




Figure 2E X-ray powder diffractograms of II B prepared by spray drying method, feed rate 15 ml/min [(A) II15B130; (B) II15B140 and (C) II15B150]




Figure 3E X-ray powder diffractograms of IIB prepared by spray drying method, feed rate 20 ml/min [(A) II20B130; (B) II20B140 and (C) II20B150]




Figure 4E X-ray powder diffractograms of IB prepared by spray drying method, feed rate 10 ml/min [(A) I10B130; (B) I10B140 and (C) I10B150]




Figure 5E X-ray powder diffractograms of IB prepared by spray drying method, feed rate 20 ml/min [(A) I20B130; (B) I20B140 and (C) I20B150]




Figure 6E X-ray powder diffractograms of IBB prepared by spray drying method, feed rate 10 ml/min [(A) I10BB130; (B) I10BB140 and (C) I10BB150]

Counts




Figure 7E X-ray powder diffractograms of IBB prepared by spray drying method, feed rate 15 ml/min [(A) I15BB130; (B) I15BB140 and (C) I15BB150]




Figure 8E X-ray powder diffractograms of IBB prepared by spray drying method, feed rate 20 ml/min [(A) I20BB130; (B) I20BB140 and (C) I20BB150]

APPENDICES F

DSC THERMOGRAMS OF SPRAY DRIED INDOMETHACIN

AND BETA CYCLODEXTRIN




Figure 1F DSC thermograms of II B prepared by spray drying method, feed rate 10 ml/min
[(A) II10B130; (B) II10B140 and (C) II10B150]




Figure 2F DSC thermograms of II B prepared by spray drying method, feed rate 15 ml/min
[(A) II15B130; (B) II15B140 and (C) II15B150]




Figure 3F DSC thermograms of II B prepared by spray drying method, feed rate 20 ml/min [(A) II20B130; (B) II20B140 and (C) II20B150]




Figure 4F DSC thermograms of IB prepared by spray drying method, feed rate 10 ml/min
[(A) I10B130; (B) I10B140 and (C) I10B150]




Figure 5F DSC thermograms of IB prepared by spray drying method, feed rate 20 ml/min
[(A) I20B130; (B) I10B140 and (C) I10B150]




Figure 6F DSC thermograms of IBB prepared by spray drying method, feed rate 10 ml/min [(A) I10BB130; (B) I10BB140 and (C) I10BB150]




Figure 7F DSC thermograms of IBB prepared by spray drying method, feed rate 15 ml/min [(A) I15BB130; (B) I15BB140 and (C) I15BB150]




Figure 8G Infrared spectra in KBr pellet of IBB prepared by spray drying method, feed rate 20 ml/min [(A) I20BB130; (B) I20BB140 and (C) I20BB150]

APPENDICES G
FTIR SPECTRA OF SPRAY DRIED INDOMETHACIN
AND BETA CYCLODETRIN




Figure 1G Infrared spectra in KBr pellet of II B prepared by spray drying method, feed rate 10 ml/min [(A) II10B130; (B) II10B140 and (C) II10B150]




Figure 2G Infrared spectra in KBr pellet of II B prepared by spray drying method, feed rate 15 ml/min [(A) II15B130; (B) II15B140 and (C) II15B150]




Figure 3G Infrared spectra in KBr pellet of II20B prepared by spray drying method, feed rate 20 ml/min [(A) II20B130; (B) II20B140 and (C) II20B150]




Figure 4G Infrared spectra in KBr pellet of IB prepared by spray drying method, feed rate 10 ml/min [(A) I10B130; (B) I10B140 and (C) I10B150]




Figure 5G Infrared spectra in KBr pellet of IB prepared by spray drying method, feed rate 20 ml/min [(A) I20B130; (B) I20B140 and (C) I20B150]




Figure 6G Infrared spectra in KBr pellet of IBB prepared by spray drying method, feed rate 10 ml/min [(A) I10BB130; (B) I10BB140 and (C) I10BB150]




Figure 7G Infrared spectra in KBr pellet of IBB prepared by spray drying method, feed rate 15 ml/min [(A) I15BB130; (B) I15BB140 and (C) I15BB150]




Figure 8G Infrared spectra in KBr pellet of IBB prepared by spray drying method, feed rate 20 ml/min [(A) I20BB130; (B) I20BB140 and (C) I20BB150]

APPENDIX H

Solubility of Indomethacin, Physical Mixtures and Spray Dried Products

TABLE 1H Solubility of IMC and Spray dried IMC in phosphate buffer pH 7.4

Time (hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)									
	IMC					Spray dried IMC				
	1	2	3	average	SD	1	2	3	average	SD
0.5	932.68	1031.20	1014.78	992.88	52.78	4325.12	4423.65	4399.01	4382.59	51.27
1	1096.88	1113.30	1014.78	1074.99	52.78	9300.49	9349.75	9325.12	9325.12	24.63
2	1425.29	1277.50	1343.19	1348.66	74.04	12206.90	11812.81	11788.18	11935.96	234.96
4	1480.97	1277.50	1343.19	1370.55	109.33	12182.27	11960.59	11837.44	11993.43	174.74
6	1544.83	1594.09	1667.98	1602.30	61.99	12477.83	9965.52	9793.10	10745.48	1502.73
12	1845.32	1736.95	1909.36	1830.54	87.15	12354.68	10482.76	11221.67	11353.04	942.85
24	1717.24	1869.95	1786.21	1791.13	76.47	12256.16	12256.16	11073.89	11862.07	682.58
30	1933.99	1835.47	1840.39	1869.95	55.51	12256.16	12231.53	11960.59	12149.43	164.00
48	1830.54	1840.39	1722.17	1797.70	65.60	12280.79	12231.53	11960.59	12157.64	172.41
72	1771.43	1963.55	1751.72	1828.90	117.02	12256.16	12059.11	12034.48	12116.58	121.50

TABLE 2H Solubility of IB in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	I10B130					I10B140					I10B150				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	20541.87	21157.64	20788.18	20829.23	309.93	23004.93	23086.50	23251.23	23107.55	128.18	36859.61	27068.97	21588.67	28505.75	7736.19
1	20849.75	21773.40	33103.45	25242.20	6823.69	26576.35	27315.27	26945.81	26945.81	369.46	37475.37	27931.03	25160.10	30188.83	6460.63
2	38891.63	37229.06	44802.96	40307.88	3980.61	35443.35	39568.97	39014.78	38009.03	2239.16	40960.59	40960.59	41453.20	41124.79	284.41
4	40837.44	37389.16	41576.35	39934.32	2234.92	40837.44	36773.40	32586.21	36732.35	4125.77	40960.59	39729.06	46502.46	42397.37	3608.05
6	43300.49	37758.62	38867.00	39975.37	2932.48	42068.97	37758.62	40098.52	39975.37	2157.81	40960.59	45886.70	49088.67	45311.99	4094.40
12	45394.09	37389.16	42438.42	41740.56	4047.84	40467.98	33325.12	41330.05	38374.38	4393.98	40960.59	48596.06	48842.36	46133.00	4481.13
24	42192.12	47610.84	42068.97	43957.31	3164.65	25689.66	33571.43	36280.79	31847.29	5502.05	40960.59	46625.62	53399.01	46995.07	6227.44
30	43177.34	35172.41	30246.31	36198.69	6528.32	31724.14	35788.18	31724.14	33078.82	2346.37	40960.59	54753.69	47733.99	47816.09	6896.92
48	43793.10	41699.51	47980.30	44490.97	3198.02	45640.39	40467.98	41699.51	42602.63	2701.89	40960.59	51182.27	53275.86	48472.91	6589.53
72	58860.84	42931.03	49827.59	50539.82	7988.75	46379.31	42192.12	43054.19	43875.21	2211.04	40960.59	51305.42	53768.47	48678.16	6796.13

TABLE 3H Solubility of IB in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	I15B130					I15B140					I15B150				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	18694.58	21157.64	20788.18	20213.46	1328.30	19310.34	20603.45	20541.87	20151.89	729.45	18694.58	20911.33	18509.85	19371.92	1336.36
1	19187.19	21773.40	33103.45	24688.01	7401.81	25344.83	25467.98	25714.29	25509.03	188.12	20295.57	21773.40	19310.34	20459.77	1239.71
2	31317.73	37229.06	44802.96	37783.25	6759.67	39692.12	34704.43	37967.98	37454.84	2533.13	36674.88	40862.07	44802.96	40779.97	4064.66
4	32733.99	37389.16	41576.35	37233.17	4423.25	40837.44	39359.61	40714.29	40303.78	819.99	37635.47	37266.01	37635.47	37512.32	213.31
6	38583.74	37758.62	38867.00	38403.12	575.84	32463.05	44285.71	40837.44	39195.40	6079.97	38867.00	37758.62	38867.00	38497.54	639.92
12	45541.87	37389.16	42438.42	41789.82	4114.87	37635.47	40098.52	37881.77	38538.59	1356.54	44778.33	37389.16	42438.42	41535.30	3776.46
24	47241.38	47610.84	42068.97	45640.39	3098.46	35541.87	40837.44	40591.13	38990.15	2988.83	40221.67	47610.84	42068.97	43300.49	3845.44
30	47857.14	35172.41	30246.31	37758.62	9085.80	41945.81	36527.09	46009.85	41494.25	4757.48	43054.19	35172.41	30246.31	36157.64	6460.53
48	56847.29	41699.51	47980.30	48842.36	7610.60	34926.11	36773.40	43546.80	38415.44	4538.86	42931.03	41699.51	47980.30	44203.61	3328.16
72	44778.33	42931.03	49827.59	45845.65	3570.01	35788.18	42192.12	43054.19	40344.83	3969.65	43546.80	42931.03	49827.59	45435.14	3816.41

TABLE 4H Solubility of IB in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	I20B130					I20B140					I20B150				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	35812.81	28854.68	29408.87	31358.78	3867.24	33598.06	34458.13	33041.87	33698.69	713.68	34150.25	33103.45	35566.50	34273.40	1236.14
1	41822.66	41945.81	41576.35	41781.61	188.12	37266.01	38743.84	37266.01	37758.62	853.23	39975.37	37266.01	38743.84	38661.74	1356.54
2	40098.52	40467.98	41083.74	40550.08	497.72	39236.45	33201.97	36896.55	36444.99	3042.48	41330.05	43546.80	41822.66	42233.17	1163.99
4	42931.03	45270.94	38004.93	42068.97	3708.92	44532.02	37266.01	38374.38	40057.47	3914.50	41576.35	39482.76	43916.26	41658.46	2217.89
6	48226.60	50935.98	45394.09	48185.55	2771.16	37142.86	40467.98	42561.58	40057.47	2732.58	42684.73	45763.55	48596.06	45681.44	2956.52
12	47980.30	45270.94	39113.30	44121.51	4543.87	43177.34	43423.65	46748.77	44449.92	1994.67	48226.60	51059.11	44162.56	47816.09	3466.55
24	43054.19	36157.64	55738.92	44983.58	9932.20	49827.59	44901.48	41576.35	45435.14	4151.42	43793.10	46379.31	46256.16	45476.19	1458.90
30	41330.05	45394.09	45763.55	44162.56	2459.97	54384.24	44162.56	35049.26	44532.02	9672.78	46379.31	51428.57	48226.60	48678.16	2554.74
48	46625.62	40714.29	45517.24	44285.71	3142.20	41945.81	43916.26	36157.64	40673.23	4032.82	46625.62	46625.62	44285.71	45845.65	1350.94
72	46748.77	39482.76	45886.70	44039.41	3969.65	42315.27	43300.49	36773.40	40796.39	3518.66	47733.99	46502.46	45024.63	46420.36	1356.54

TABLE 5H Solubility of IBB in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	I10BB130					I10BB140					I10BB150				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	6788.18	5655.17	4029.56	5490.97	1386.62	5310.34	5162.56	4645.32	5039.41	349.20	6270.94	6517.24	7009.85	6599.34	376.24
1	11714.29	8118.23	8955.67	9596.06	1881.62	9004.93	8118.23	8216.75	8446.63	486.00	8980.30	9472.91	9965.52	9472.91	492.61
2	14177.34	13044.33	13758.62	13660.10	572.89	15778.33	15285.71	17083.74	16049.26	929.13	15778.33	15285.71	17083.74	16049.26	929.13
4	19596.06	17330.05	17182.27	18036.12	1352.96	18807.88	18266.01	17871.92	18315.27	469.92	18807.88	18266.01	17871.92	18315.27	469.92
6	18571.43	19371.92	22635.47	20192.94	2152.83	22019.70	22820.20	23559.11	22799.67	769.91	22019.70	22820.20	23559.11	22799.67	769.91
12	22081.28	20849.75	20849.75	21260.26	711.02	22943.35	26022.17	24174.88	24380.13	1549.64	22019.70	26022.17	24174.88	24072.25	2003.20
24	18386.70	17524.83	17832.51	17914.61	438.86	19618.23	21527.09	21157.64	20767.65	1012.43	22019.70	21527.09	21157.64	21568.14	432.50
30	18448.28	17709.38	17463.05	17873.56	512.73	19802.96	18879.31	22573.89	20418.72	1922.72	22019.70	18879.31	22573.89	21157.64	1992.45
48	17832.51	17647.78	19064.04	18181.44	769.91	25036.95	18879.31	19002.46	20972.91	3520.10	22019.70	18879.31	19002.46	19967.16	1778.62
72	17586.21	19371.92	18325.12	18427.75	897.27	27992.61	19002.46	20110.84	22368.64	4901.93	22019.70	19002.46	20110.84	20377.67	1526.22

TABLE 6H Solubility of IBB in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	I15BB130					I15BB140					I15BB150				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	8349.75	7980.30	9458.13	8596.06	769.09	8965.52	9827.59	9273.40	9355.50	436.86	4571.43	4916.26	4768.47	4752.05	173.00
1	12044.33	15985.22	13152.71	13727.42	2032.33	13275.86	12906.40	12721.67	12967.98	282.18	6788.18	7379.31	8955.67	7707.72	1120.44
2	17032.02	17216.75	16477.83	16908.87	384.54	18017.24	15554.19	16354.68	16642.04	1256.42	12970.44	11394.09	11935.96	12100.16	800.90
4	14507.39	16785.71	13830.05	15041.05	1548.41	22758.62	19310.34	20357.14	20808.70	1767.93	22157.64	16763.55	19177.34	19366.17	2702.00
6	20233.99	18571.43	17647.78	18817.73	1310.58	24174.88	23189.66	23004.83	23456.49	628.96	22573.89	21034.48	21280.79	21629.72	826.90
12	17339.90	18263.55	17524.63	17709.36	488.75	22697.04	21650.25	21219.21	21855.50	760.00	21157.64	20357.14	20849.75	20788.18	403.78
24	14938.42	16662.56	19433.50	17011.49	2267.76	23004.93	19741.38	24667.49	22471.26	2506.04	20295.57	14384.24	16416.26	17032.02	3003.39
30	18140.39	21588.67	17155.17	18961.41	2327.99	25899.01	23128.08	19002.46	22676.52	3470.38	20541.87	18509.85	20603.45	19885.06	1191.36
48	17770.94	15985.22	16477.83	16744.66	922.28	22697.04	21034.48	24975.37	22902.30	1978.44	19864.53	17524.63	19987.68	19125.62	1387.86
72	18386.70	17524.63	16169.95	17360.43	1117.46	25467.98	23435.96	24298.03	24400.66	1019.89	19433.50	19495.07	19679.80	19536.12	128.18

TABLE 7H Solubility of IBB in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	I20BB130					I20BB140					I20BB150				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	4078.82	3832.51	4399.01	4103.45	284.05	4078.82	3586.21	4029.56	3898.19	271.31	3832.51	4078.82	4152.71	4021.35	167.66
1	5802.98	6485.22	6000.00	6096.06	351.13	5558.65	5310.34	5753.69	5540.23	222.13	5802.96	5558.65	5753.69	5704.43	130.33
2	10729.06	10655.17	10482.76	10622.33	126.39	9448.28	8660.10	8571.43	9226.60	494.45	10729.06	10901.48	9793.10	10474.55	596.41
4	14845.32	14448.28	10827.59	13307.06	2149.55	13083.60	11295.57	15162.56	13183.91	1935.08	13438.42	13980.30	13881.77	13766.83	288.64
6	18241.38	16418.72	17403.94	17354.68	912.33	20556.65	16443.35	18561.58	18520.53	2056.96	18758.62	16738.92	18807.88	18101.81	1180.55
12	21465.52	19926.11	20972.91	20788.18	786.15	19864.53	15123.15	18940.89	17976.19	2513.59	19802.96	21958.13	20233.99	20665.02	1140.41
24	18879.31	18694.58	19433.50	19002.46	384.54	18325.12	20911.33	17647.78	18961.41	1722.30	19987.68	16662.56	19926.11	18858.78	1902.23
30	20172.41	19310.34	21896.55	20459.77	1316.83	21773.40	19248.77	20049.26	20357.14	1290.17	21650.25	19002.46	22327.59	20993.43	1757.18
48	17463.05	16293.10	18571.43	17442.53	1139.30	16847.29	18386.70	17524.63	17586.21	771.55	19556.65	18201.97	18017.24	18591.95	840.54
72	17586.21	17093.60	17155.17	17278.33	268.41	18078.82	19002.46	16847.29	17976.19	1081.25	18448.28	19694.58	19926.11	19022.99	791.76

TABLE 8H Solubility of IMC/BCD physical mixtures in phosphate buffer pH 7.4

Times (Hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)														
	IIB(PM)					IB(PM)					IBB(PM)				
	1	2	3	average	SD	1	2	3	average	SD	1	2	3	average	SD
0.5	2970.44	3044.33	3142.86	3052.55	86.50	3044.33	3290.64	3389.16	3241.38	177.61	3044.33	3142.86	3167.49	3118.23	65.17
1	4054.19	4128.08	4078.82	4087.03	37.62	4054.19	4029.56	4103.45	4062.40	37.62	3290.64	3167.49	3266.01	3241.38	65.17
2	5162.56	5729.06	5211.82	5367.82	313.82	6517.24	6443.35	6467.98	6476.19	37.62	5261.08	4867.00	5137.93	5088.67	201.61
4	6591.13	6911.33	7059.11	6853.86	239.22	7921.18	8142.86	7921.18	7995.07	127.98	7921.18	7699.51	7551.72	7724.14	185.96
6	8093.60	8586.21	10113.30	8931.03	1053.08	7600.99	7699.51	7551.72	7617.41	75.25	7527.09	7970.44	7773.40	7756.98	222.13
12	8733.99	8857.14	8290.64	8627.26	297.95	8019.70	8192.12	8019.70	8077.18	99.54	7527.09	8266.01	7847.29	7880.13	370.55
24	7871.92	7945.81	9399.01	8405.58	861.13	8536.95	8857.14	10113.30	9169.13	833.20	7403.94	8044.33	8118.23	7855.50	392.80
30	8339.90	8684.73	9842.36	8955.67	787.02	10261.08	9719.21	9177.34	9719.21	541.87	7798.03	7871.92	8315.27	7995.07	279.75
48	9029.56	8290.64	9522.17	8947.45	619.86	10655.17	8857.14	9152.71	9555.01	964.16	8413.79	8315.27	8339.90	8356.32	51.27
72	9448.28	8733.99	10113.30	9431.86	689.80	10630.54	9916.26	10113.30	10220.03	368.91	7724.14	7453.20	8118.23	7765.19	334.41

TABLE 9H Solubility of IS in phosphate buffer pH 7.4

Time (hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)									
	IS13					IS20				
	1	2	3	average	SD	1	2	3	average	SD
0.5	14384.24	14568.97	15000.00	14651.07	315.99	20541.87	20233.99	20480.30	20418.72	162.92
1	19310.34	19926.11	20541.87	19926.11	615.76	25467.98	25775.86	25714.29	25652.71	162.92
2	30147.78	22943.35	28731.53	27274.22	3816.91	39137.93	32056.65	40800.49	37331.69	4643.34
4	28854.68	19248.77	25591.13	24564.86	4884.50	37512.32	32832.51	35788.18	35377.67	2366.75
6	27438.42	23620.69	26330.05	25798.39	1964.02	35541.87	34187.19	33940.89	34556.65	862.07
12	27746.31	23867.00	24359.61	25324.30	2111.93	30000.00	32463.05	27906.40	30123.15	2280.82
24	29408.87	26022.17	25529.56	26988.86	2111.93	21009.85	20886.70	21009.85	20968.80	71.10
30	15677.34	13460.59	13091.13	14076.35	1398.75	16822.66	18669.95	15837.44	17110.02	1437.95
48	12650.25	10655.17	11665.02	11656.81	997.56	16785.71	15246.31	16416.26	16149.43	803.64
72	10901.48	11443.35	11689.66	11344.83	403.22	14938.42	17032.02	14630.54	15533.66	1306.72

TABLE 10H Solubility of IS in phosphate buffer pH 7.4

Time (hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)									
	IS27					IS33				
	1	2	3	average	SD	1	2	3	average	SD
0.5	6492.61	5827.59	6246.31	6188.83	336.22	6246.31	6320.20	6369.46	6311.99	61.99
1	8955.67	8463.05	8487.68	8835.47	277.57	8463.05	8536.95	8832.51	8610.84	195.50
2	16935.96	36613.30	16862.07	23470.44	11382.11	14793.10	39384.24	15162.56	23113.30	14092.25
4	16724.14	18817.73	14261.08	16600.99	2280.82	15923.65	16847.29	15431.03	16067.32	718.98
6	16662.56	17463.05	12844.83	15656.81	2467.92	13953.20	15738.92	12290.64	13994.25	1724.50
12	16662.56	17709.36	18201.97	17524.63	786.15	18140.39	17586.21	18879.31	18201.97	648.75
24	15307.88	15307.88	13645.32	14753.69	959.88	13152.71	15554.19	15307.88	14671.59	1321.14
30	15184.73	19926.11	12413.79	15841.54	3798.98	13460.59	22943.35	15862.07	17422.00	4930.08
48	14753.69	16847.29	12598.52	14733.17	2124.46	16477.83	17586.21	17155.17	17073.07	558.73
72	14692.12	16293.10	12536.95	14507.39	1884.88	16354.68	16539.41	16847.29	16580.46	248.86

TABLE 11H Solubility of IMC/SLS physical mixtures in phosphate buffer pH 7.4

Time (hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)									
	IS13(PM)					IS20(PM)				
	1	2	3	average	SD	1	2	3	average	SD
0.5	1645.32	1399.01	1522.17	1522.17	123.15	1435.96	1448.28	1571.43	1485.22	74.91
1	1953.20	1768.47	2014.78	1912.15	128.18	2076.35	1845.32	2076.35	1932.68	248.86
2	3862.07	2729.06	3738.92	3443.35	621.65	3763.55	3209.36	4145.32	3706.08	470.62
4	3985.22	3184.73	3862.07	3677.34	431.03	4046.80	3307.88	4169.95	3841.54	466.25
6	4157.64	4071.43	4330.05	4186.37	131.68	4145.32	3332.51	4330.05	3935.96	530.70
12	4440.89	3874.38	4268.47	4194.58	290.39	4169.95	4046.80	4169.95	4128.90	71.10
24	4258.16	3948.28	4687.19	4297.21	371.16	4600.99	4022.17	4871.92	4498.36	434.07
30	4145.32	4145.32	4256.16	4182.27	63.99	4588.67	4182.27	4798.03	4522.99	313.09
48	4231.53	3751.23	3160.10	3714.29	536.67	3788.18	4096.06	4379.31	4087.85	295.65
72	3566.50	3751.23	3997.54	3771.76	216.25	4403.94	4293.10	4243.84	4313.63	82.00

TABLE 12H Solubility of IMC/SLS physical mixtures in phosphate buffer pH 7.4

Time (hours)	Concentration of Indomethacin ($\times 10^{-3}$ mcg/ml)									
	IS27(PM)					IS33(PM)				
	1	2	3	average	SD	1	2	3	average	SD
0.5	1620.69	1583.74	1768.47	1657.64	97.75	1460.59	1423.65	1583.74	1489.33	83.83
1	2815.27	3061.58	2568.97	2815.27	246.31	2827.59	2815.27	2839.90	2827.59	12.32
2	5623.15	6004.93	5438.42	5688.83	288.91	5549.26	5426.11	5512.32	5495.89	63.20
4	5647.78	6263.55	5093.60	5668.31	585.25	5647.78	5032.02	5524.63	5401.48	325.83
6	5783.25	6485.22	4440.89	5569.79	1038.75	5857.14	5192.12	5746.31	5598.52	356.29
12	5007.39	6509.85	5253.69	5590.31	805.81	5610.84	6226.60	5389.16	5742.20	433.90
24	4625.62	5413.79	5770.94	5270.11	586.02	6017.24	6325.12	6325.12	6222.50	177.76
30	5684.73	5746.31	6078.82	5836.62	212.00	6399.01	6189.66	5770.94	6119.87	319.80
48	5906.40	5783.25	5955.67	5881.77	88.81	5857.14	6177.34	5869.46	5967.98	181.42
72	5943.35	5118.23	5684.73	5582.10	422.03	5783.25	4970.44	5561.58	5438.42	420.17

APPENDIX I

DISSOLUTION DATA

Table 1I Dissolution data of IMC

Time (min)	% release			Average	SD	% CV
	1	2	3			
6	45.52	47.04	49.72	47.43	2.13	4.48
8	52.18	54.04	53.54	53.25	0.96	1.81
10	54.48	58.76	56.31	56.52	2.15	3.80
12	60.68	59.66	60.77	60.37	0.62	1.02
15	62.15	64.12	63.05	63.11	0.99	1.56
20	67.51	66.70	68.91	67.71	1.12	1.65
30	70.28	71.98	73.01	71.76	1.38	1.92
40	74.48	74.77	75.86	75.04	0.73	0.97
60	79.57	78.33	80.19	79.36	0.95	1.19

Table 2I Dissolution data of II10B130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	49.12	68.24	42.76	53.37	13.26	24.85
8	62.21	75.03	65.23	67.49	6.70	9.93
10	82.36	89.54	85.81	85.90	3.59	4.18
12	88.55	93.87	87.70	90.04	3.34	3.71
15	95.14	95.72	97.78	96.21	1.39	1.44
20	95.24	97.90	99.19	97.44	2.01	2.07
30	96.12	97.69	101.09	98.30	2.54	2.58
40	96.52	97.10	99.38	97.67	1.51	1.55
60	96.59	96.69	99.43	97.57	1.61	1.65

Table 3I Dissolution data of II10B140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	79.92	68.12	70.32	72.79	6.27	8.62
8	96.79	93.99	94.73	95.17	1.45	1.52
10	101.58	101.67	101.06	101.44	0.33	0.33
12	103.59	103.05	103.11	103.25	0.29	0.28
15	103.04	103.27	103.33	103.21	0.15	0.15
20	103.50	103.90	103.52	103.64	0.22	0.22
30	102.64	104.38	103.87	103.63	0.89	0.86
40	104.59	104.24	104.47	104.43	0.18	0.17
60	104.82	104.35	105.37	104.85	0.51	0.49

Table 4I Dissolution data of II10B150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	55.08	69.96	63.04	62.69	7.45	11.88
8	70.97	91.77	97.72	86.82	14.04	16.17
10	80.75	101.90	103.52	95.39	12.70	13.32
12	92.77	105.91	104.04	100.91	7.11	7.05
15	101.41	107.75	105.68	104.95	3.24	3.08
20	107.91	108.78	106.92	107.87	0.93	0.86
30	108.45	108.71	106.11	107.76	1.43	1.33
40	108.86	108.92	105.87	107.88	1.74	1.62
60	108.96	107.25	105.81	107.34	1.58	1.47

Table 5I Dissolution data of II15B130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	47.52	41.08	40.08	42.89	4.04	9.41
8	71.27	70.11	59.76	67.05	6.34	9.45
10	96.34	94.44	81.77	90.85	7.92	8.72
12	105.72	103.95	97.49	102.39	4.33	4.23
15	106.26	104.74	104.50	105.17	0.95	0.91
20	106.73	105.74	105.36	105.94	0.71	0.67
30	106.83	106.28	105.71	106.27	0.56	0.53
40	106.96	106.34	105.84	106.38	0.56	0.53
60	106.94	106.81	105.91	106.55	0.56	0.53

Table 6I Dissolution data of II15B140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	46.40	32.04	37.68	38.71	7.23	18.69
8	81.94	65.43	55.71	67.69	13.26	19.59
10	104.34	98.05	82.20	94.86	11.41	12.03
12	105.38	102.38	100.15	102.64	2.62	2.56
15	106.08	103.99	102.28	104.12	1.90	1.83
20	106.36	104.05	103.49	104.63	1.52	1.45
30	106.09	104.73	104.54	105.12	0.85	0.80
40	106.81	104.34	105.21	105.45	1.25	1.19
60	106.04	104.63	105.27	105.31	0.71	0.67

Table 7I Dissolution data of II15B150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	45.39	31.01	35.55	37.32	7.35	19.70
8	79.84	64.33	53.21	65.79	13.38	20.33
10	100.34	97.02	80.15	92.50	10.83	11.70
12	101.38	101.15	96.15	99.56	2.96	2.97
15	102.40	102.98	98.28	101.22	2.56	2.53
20	103.31	103.05	102.49	102.95	0.42	0.41
30	104.09	103.45	103.04	103.53	0.53	0.51
40	104.71	104.23	103.11	104.02	0.82	0.79
60	105.04	105.15	103.17	104.45	1.11	1.07

Table 8I Dissolution data of II20B130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	42.32	32.04	69.12	47.83	19.14	40.03
8	71.48	50.47	88.76	70.24	19.18	27.30
10	92.99	85.69	101.87	93.52	8.10	8.66
12	103.25	98.77	103.67	101.90	2.72	2.67
15	103.67	104.40	104.03	104.03	0.37	0.35
20	104.58	104.54	105.01	104.71	0.26	0.25
30	105.03	104.63	104.76	104.81	0.20	0.19
40	105.06	105.04	105.09	105.06	0.03	0.02
60	105.08	105.17	105.15	105.13	0.05	0.04

Table 9I Dissolution data of II20B140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	80.68	75.00	87.36	81.01	6.19	7.64
8	101.44	101.32	100.63	101.13	0.43	0.43
10	105.21	105.86	104.70	105.26	0.58	0.55
12	106.78	106.40	106.73	106.64	0.21	0.20
15	108.16	105.09	107.56	106.93	1.63	1.52
20	107.05	107.06	106.15	106.75	0.52	0.49
30	106.87	105.56	105.76	106.06	0.71	0.67
40	106.07	105.35	105.83	105.75	0.37	0.35
60	106.36	107.15	105.40	106.31	0.88	0.82

Table 10I Dissolution data of II20B150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	55.12	64.72	87.56	69.13	16.66	24.10
8	87.09	83.10	91.49	87.23	4.20	4.81
10	100.97	100.21	100.97	100.72	0.44	0.44
12	101.81	101.01	103.32	102.05	1.17	1.15
15	105.08	105.48	103.66	104.74	0.96	0.92
20	105.63	105.99	103.49	105.04	1.35	1.29
30	104.98	106.15	104.28	105.14	0.94	0.90
40	104.94	106.09	105.23	105.42	0.60	0.57
60	104.89	106.30	105.27	105.49	0.73	0.69

Table 11I Dissolution data of I10B130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	43.96	36.92	49.08	43.32	6.11	14.09
8	72.27	70.53	77.71	73.50	3.74	5.09
10	93.66	92.67	94.70	93.68	1.02	1.08
12	101.33	98.19	95.22	98.25	3.06	3.11
15	103.84	101.15	99.40	101.46	2.24	2.21
20	102.97	101.92	102.37	102.42	0.53	0.52
30	103.40	102.11	103.36	102.96	0.73	0.71
40	101.56	102.77	103.81	102.71	1.12	1.09
60	105.93	104.43	104.01	104.79	1.01	0.96

Table 12I Dissolution data of I10B140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	40.16	39.80	44.24	41.40	2.47	5.96
8	78.74	76.65	75.63	77.01	1.59	2.06
10	104.24	101.20	100.11	101.85	2.14	2.10
12	105.29	103.41	102.18	103.63	1.57	1.51
15	106.26	104.36	103.17	104.60	1.56	1.49
20	106.46	105.28	103.73	105.16	1.37	1.30
30	106.53	105.42	104.56	105.50	0.99	0.94
40	106.30	105.50	104.42	105.41	0.94	0.89
60	106.92	106.13	105.09	106.05	0.92	0.87

Table 13I Dissolution data of I10B150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	33.80	39.80	44.24	39.28	5.24	13.34
8	88.65	86.65	85.63	86.98	1.54	1.77
10	100.16	101.20	101.89	101.08	0.87	0.86
12	103.21	103.41	102.14	102.92	0.68	0.66
15	104.18	104.36	102.17	103.57	1.22	1.17
20	104.38	105.28	102.73	104.13	1.29	1.24
30	105.45	105.42	103.56	104.81	1.08	1.03
40	106.21	105.50	104.42	105.38	0.90	0.86
60	106.83	106.13	105.09	106.02	0.88	0.83

Table 14I Dissolution data of I15B130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	70.92	84.00	67.96	74.29	8.54	11.49
8	85.87	99.68	92.67	92.74	6.91	7.45
10	92.60	101.53	98.66	97.60	4.56	4.67
12	99.84	102.59	104.72	102.38	2.44	2.39
15	101.13	103.11	103.42	102.55	1.24	1.21
20	102.94	101.49	105.57	103.33	2.07	2.00
30	102.71	102.43	105.70	103.62	1.81	1.75
40	104.35	102.26	105.01	103.87	1.44	1.38
60	103.43	102.86	107.45	104.58	2.50	2.39

Table 15I Dissolution data of I15B140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	65.72	60.92	68.72	65.12	3.93	6.04
8	85.32	73.93	85.31	81.52	6.57	8.06
10	97.52	93.19	93.27	94.66	2.48	2.62
12	99.09	103.26	97.55	99.97	2.95	2.96
15	100.19	104.07	100.33	101.53	2.20	2.17
20	101.59	104.12	100.21	101.97	1.98	1.94
30	101.64	104.18	100.60	102.14	1.84	1.80
40	102.36	105.10	99.61	102.36	2.75	2.68
60	102.41	105.46	99.27	102.38	3.10	3.02

Table 16I Dissolution data of I15B150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	90.40	65.44	87.08	80.97	13.55	16.74
8	100.25	81.95	98.55	93.58	10.11	10.80
10	101.04	95.15	101.44	99.21	3.52	3.55
12	101.63	97.76	102.55	100.64	2.54	2.53
15	101.25	100.54	101.01	100.93	0.36	0.36
20	100.33	99.26	104.50	101.36	2.77	2.73
30	102.42	101.35	103.01	102.26	0.84	0.83
40	101.80	100.28	100.62	100.90	0.80	0.79
60	104.68	101.67	102.47	102.94	1.56	1.51

Table 17I Dissolution data of I20B130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	70.24	58.36	51.40	60.00	9.53	15.88
8	88.18	72.62	75.21	78.67	8.34	10.60
10	98.86	87.37	83.72	89.98	7.90	8.78
12	99.35	92.74	92.62	94.90	3.85	4.06
15	100.95	96.46	100.01	99.14	2.37	2.39
20	101.79	98.33	100.12	100.08	1.73	1.73
30	100.55	99.58	100.54	100.22	0.56	0.56
40	100.40	99.78	100.19	100.12	0.31	0.31
60	101.46	99.73	100.14	100.44	0.90	0.90

Table 18I Dissolution data of I20B140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	35.08	30.88	31.64	32.53	2.24	6.88
8	47.23	47.77	49.26	48.09	1.05	2.19
10	79.93	78.82	65.43	74.73	8.07	10.80
12	93.80	94.15	82.69	90.21	6.51	7.22
15	103.11	96.54	93.69	97.78	4.83	4.94
20	103.91	97.78	94.35	98.68	4.84	4.91
30	103.66	96.86	93.92	98.15	5.00	5.09
40	104.63	96.92	94.36	98.64	5.35	5.42
60	104.20	96.92	94.62	98.58	5.00	5.07

Table 19I Dissolution data of I20B150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	39.88	30.80	64.28	44.99	17.31	38.49
8	66.33	72.29	81.44	73.35	7.61	10.37
10	83.61	96.89	96.00	92.16	7.42	8.05
12	97.95	102.84	103.52	101.44	3.04	2.99
15	98.72	103.34	104.55	102.20	3.07	3.01
20	103.39	103.90	105.04	104.11	0.84	0.81
30	105.03	104.26	105.90	105.06	0.82	0.78
40	105.34	104.77	105.90	105.34	0.57	0.54
60	105.49	105.10	106.73	105.77	0.85	0.80

Table 20I Dissolution data of I10BB130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	43.64	54.92	60.36	52.97	8.53	16.10
8	80.62	83.41	92.77	85.60	6.37	7.44
10	104.49	95.11	98.85	99.48	4.72	4.75
12	105.66	98.71	99.31	101.23	3.85	3.80
15	107.83	100.81	98.47	102.37	4.87	4.76
20	109.41	101.33	99.14	103.29	5.41	5.24
30	106.51	99.33	100.73	102.19	3.81	3.73
40	106.43	100.24	99.81	102.16	3.71	3.63
60	106.10	100.26	100.25	102.20	3.37	3.30

Table 21 Dissolution data of I10BB140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	97.52	95.04	90.80	94.45	3.40	3.60
8	100.08	101.92	99.14	100.38	1.41	1.41
10	100.39	104.15	100.75	101.76	2.07	2.04
12	101.30	104.99	101.55	102.61	2.06	2.01
15	101.55	106.12	101.52	103.06	2.65	2.57
20	100.66	106.35	101.24	102.75	3.13	3.05
30	100.12	105.58	100.66	102.12	3.01	2.95
40	99.39	105.84	101.56	102.27	3.28	3.21
60	99.92	105.53	101.32	102.26	2.92	2.86

Table 22 Dissolution data of I10BB150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	69.48	58.32	47.76	58.52	10.86	18.56
8	90.45	85.82	87.86	88.04	2.32	2.63
10	98.96	99.51	94.00	97.49	3.04	3.11
12	101.41	105.13	94.50	100.35	5.40	5.38
15	101.56	106.13	94.91	100.87	5.64	5.59
20	102.37	105.77	96.11	101.41	4.90	4.83
30	102.49	106.06	96.65	101.73	4.75	4.67
40	102.56	105.65	95.52	101.25	5.19	5.13
60	101.18	105.07	95.18	100.48	4.98	4.96

Table 23I Dissolution data of I15BB130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	52.32	64.04	71.04	62.47	9.46	15.14
8	82.90	93.85	101.06	92.61	9.15	9.88
10	90.55	101.65	102.91	98.37	6.80	6.91
12	100.14	102.62	102.98	101.91	1.55	1.52
15	102.54	102.58	103.81	102.98	0.72	0.70
20	101.85	102.17	102.68	102.23	0.42	0.41
30	101.65	103.25	103.02	102.64	0.87	0.84
40	101.63	101.45	102.45	101.84	0.53	0.52
60	101.39	103.05	104.25	102.90	1.43	1.39

Table 24I Dissolution data of I15BB140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	25.42	19.84	25.60	23.62	3.27	13.86
8	32.20	38.22	46.45	38.96	7.15	18.36
10	80.73	90.16	93.15	88.01	6.48	7.36
12	94.06	92.80	94.83	93.89	1.02	1.09
15	94.81	93.95	95.89	94.89	0.97	1.03
20	95.20	93.65	96.51	95.12	1.43	1.51
30	94.78	93.97	96.80	95.19	1.46	1.53
40	95.98	94.23	95.54	95.25	0.91	0.96
60	95.18	94.31	98.05	95.85	1.96	2.04

Table 25I Dissolution data of I15BB150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	51.52	53.48	51.00	52.00	1.31	2.52
8	85.05	85.49	86.67	85.74	0.84	0.98
10	90.91	90.93	90.85	90.90	0.04	0.05
12	99.65	99.83	100.75	100.08	0.59	0.59
15	100.32	98.71	99.69	99.57	0.81	0.81
20	100.36	100.03	100.40	100.26	0.20	0.20
30	103.10	100.50	102.70	102.10	1.40	1.37
40	102.88	103.09	102.35	102.77	0.38	0.37
60	102.24	103.41	103.58	103.08	0.73	0.71

Table 26I Dissolution data of I20BB130

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	53.64	50.04	51.84	51.84	1.80	3.47
8	95.92	93.39	92.54	93.95	1.76	1.87
10	102.34	103.02	104.53	103.30	1.12	1.08
12	103.68	105.01	108.19	105.63	2.32	2.19
15	103.78	103.66	104.67	104.04	0.55	0.53
20	92.50	104.30	102.01	99.61	6.26	6.28
30	94.90	103.09	103.76	100.58	4.94	4.91
40	93.79	107.09	108.08	102.99	7.98	7.75
60	105.49	109.17	109.63	108.10	2.27	2.10

Table 27I Dissolution data of I20BB140

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	52.48	57.68	62.20	57.45	4.86	8.47
8	77.94	80.86	86.72	81.84	4.47	5.46
10	88.85	91.07	93.28	91.07	2.22	2.43
12	95.14	99.63	100.46	98.41	2.86	2.91
15	100.69	103.68	106.00	103.46	2.66	2.57
20	101.37	102.00	107.13	103.50	3.16	3.05
30	102.45	100.83	106.27	103.18	2.79	2.71
40	100.64	101.71	107.57	103.31	3.73	3.61
60	101.48	101.67	106.44	103.19	2.81	2.73

Table 28I Dissolution data of I20BB150

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	86.32	88.72	85.40	86.81	1.71	1.97
8	98.15	98.74	97.36	98.09	0.69	0.70
10	99.04	99.44	98.43	98.97	0.51	0.52
12	100.29	100.18	99.49	99.99	0.43	0.43
15	99.59	100.50	99.13	99.74	0.70	0.70
20	100.73	100.61	98.75	100.03	1.11	1.11
30	99.70	99.95	100.78	100.14	0.56	0.56
40	99.73	100.22	99.61	99.85	0.32	0.32
60	99.70	99.92	99.59	99.74	0.17	0.17

Table 29I Dissolution data of IIB(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	59.87	59.51	57.48	58.95	1.29	2.19
8	60.25	62.00	65.54	62.60	2.69	4.30
10	61.42	65.16	68.97	65.18	3.78	5.79
12	62.20	69.60	70.89	67.56	4.69	6.94
15	67.47	67.46	66.68	67.20	0.45	0.67
20	71.76	73.31	73.72	72.93	1.03	1.41
30	76.15	77.99	78.97	77.70	1.43	1.85
40	82.93	83.33	85.05	83.77	1.12	1.34
60	85.44	85.72	86.86	86.00	0.75	0.87

Table 30I Dissolution data of IB(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	53.52	55.99	57.92	55.81	2.21	3.95
8	59.42	60.56	65.43	61.80	3.19	5.16
10	66.31	70.85	67.44	68.20	2.36	3.47
12	73.10	75.47	76.64	75.07	1.80	2.40
15	83.30	87.34	79.86	83.50	3.74	4.48
20	88.24	89.58	81.12	86.31	4.55	5.27
30	90.88	92.67	87.79	90.45	2.47	2.73
40	92.96	94.29	93.92	93.72	0.69	0.73
60	95.09	95.91	95.61	95.54	0.41	0.43

Table 31I Dissolution data of IBB(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	23.04	25.83	20.44	23.10	2.70	11.67
8	48.43	49.57	43.64	47.21	3.15	6.66
10	59.72	55.68	54.04	56.48	2.92	5.18
12	71.02	76.70	75.52	74.41	3.00	4.03
15	81.12	82.50	86.03	83.22	2.53	3.04
20	85.04	84.05	89.69	86.26	3.01	3.49
30	90.03	92.11	91.13	91.09	1.04	1.14
40	92.30	95.16	93.15	93.54	1.47	1.57
60	94.96	98.38	95.99	96.44	1.75	1.82

Table 32I Dissolution data of IS13

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	53.04	55.37	50.94	53.12	2.22	4.17
8	68.43	69.52	63.64	67.20	3.13	4.66
10	79.72	80.98	75.04	78.58	3.13	3.98
12	85.02	82.44	87.52	84.99	2.54	2.99
15	93.12	95.46	93.03	93.87	1.38	1.47
20	95.04	96.05	97.69	96.26	1.34	1.39
30	96.03	97.14	98.52	97.23	1.25	1.28
40	98.32	99.07	100.13	99.17	0.91	0.91
60	98.96	99.31	100.99	99.75	1.09	1.09

Table 33I Dissolution data of IS20

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	44.52	47.08	58.44	50.01	7.41	14.81
8	65.18	71.59	77.52	71.43	6.17	8.64
10	81.85	88.17	89.00	86.34	3.91	4.53
12	90.22	92.29	93.80	92.10	1.80	1.95
15	93.52	93.59	95.77	94.29	1.28	1.36
20	95.29	96.52	96.05	95.95	0.62	0.65
30	98.96	98.07	96.98	98.00	0.99	1.01
40	99.83	99.65	100.05	99.84	0.20	0.20
60	100.55	101.04	102.22	101.27	0.86	0.85

Table 34I Dissolution data of IS27

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	53.44	52.60	56.12	54.05	1.84	3.40
8	61.82	62.95	60.28	61.68	1.34	2.17
10	84.49	83.73	84.41	84.21	0.42	0.50
12	95.43	94.23	95.01	94.89	0.61	0.64
15	96.78	94.93	96.99	96.23	1.13	1.18
20	97.80	95.50	96.98	96.76	1.17	1.20
30	98.82	96.52	97.84	97.73	1.15	1.18
40	99.80	98.79	98.86	99.15	0.56	0.57
60	101.83	101.11	101.87	101.60	0.43	0.42

Table 35I Dissolution data of IS33

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	52.16	52.40	53.28	52.61	0.59	1.12
8	68.60	69.63	65.89	68.04	1.93	2.84
10	78.82	72.62	79.95	77.13	3.95	5.12
12	80.19	83.19	84.15	82.51	2.07	2.50
15	89.04	84.44	89.18	87.55	2.70	3.08
20	95.58	95.13	96.22	95.64	0.55	0.57
30	97.78	96.05	97.72	97.18	0.98	1.01
40	98.01	97.87	98.34	98.07	0.24	0.25
60	99.98	101.23	102.68	101.30	1.35	1.33

Table 36I Dissolution data of IS13(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	49.60	48.92	42.64	47.05	3.84	8.15
8	51.55	52.07	54.99	52.87	1.85	3.51
10	54.97	53.17	55.70	54.61	1.30	2.38
12	63.72	56.76	58.19	59.56	3.68	6.17
15	67.43	66.51	66.83	66.92	0.47	0.70
20	67.79	67.30	67.12	67.40	0.35	0.51
30	77.66	76.61	79.93	78.07	1.70	2.17
40	80.73	80.50	81.15	80.79	0.33	0.41
60	82.55	83.60	83.11	83.09	0.53	0.63

Table 37I Dissolution data of IS20(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	47.20	46.84	47.16	47.07	0.20	0.42
8	50.28	49.08	49.95	49.77	0.62	1.25
10	52.12	55.02	58.34	55.16	3.11	5.64
12	62.98	61.57	62.77	62.44	0.76	1.22
15	64.12	64.18	72.01	66.77	4.54	6.80
20	67.32	73.85	74.19	71.79	3.87	5.39
30	68.32	76.92	77.70	74.31	5.21	7.00
40	70.70	76.92	78.61	75.41	4.17	5.52
60	80.75	80.13	80.99	80.62	0.44	0.55

Table 38I Dissolution data of IS27(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	48.44	49.68	49.32	49.15	0.64	1.30
8	52.38	53.32	54.52	53.41	1.07	2.01
10	58.21	61.45	57.13	58.93	2.25	3.82
12	68.31	65.39	65.74	66.48	1.59	2.40
15	70.07	76.19	78.10	74.79	4.19	5.61
20	78.55	79.45	80.00	79.33	0.73	0.92
30	79.31	80.28	82.33	80.64	1.54	1.91
40	83.03	82.65	83.67	83.12	0.52	0.62
60	85.30	84.80	87.08	85.73	1.20	1.40

Table 39I Dissolution data of IS33(PM)

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	43.72	44.64	48.36	45.57	2.46	5.39
8	57.17	57.30	55.25	56.57	1.15	2.03
10	68.58	67.95	67.33	67.95	0.63	0.92
12	70.24	71.25	72.82	71.44	1.30	1.82
15	79.43	79.14	78.62	79.06	0.41	0.52
20	80.42	80.87	79.91	80.40	0.48	0.60
30	85.32	84.98	84.06	84.79	0.65	0.77
40	86.36	86.34	85.41	86.04	0.54	0.63
60	88.33	88.00	87.54	87.96	0.40	0.45

Table 40I Dissolution data of spray dried IMC

Time (min)	% release			Average	SD	%CV
	1	2	3			
6	58.20	58.99	62.15	59.78	2.09	3.50
8	62.72	68.46	65.50	65.56	2.87	4.38
10	70.46	70.98	72.17	71.20	0.88	1.23
12	71.49	72.02	77.76	73.76	3.48	4.71
15	75.52	73.79	84.54	77.95	5.77	7.41
20	80.16	81.72	89.85	83.91	5.20	6.20
30	88.83	90.69	90.24	89.92	0.97	1.08
40	89.93	90.39	92.95	91.09	1.63	1.79
60	95.68	88.91	94.95	93.18	3.72	3.99

VITA

Miss Alisara Thanmiksakul was born on March 21, 1972 in Bangkok, Thailand. She received her Bachelor of Science in Pharmacy Degree from the faculty of Pharmacy, Silpakorn University, Thailand in 1994.

